Download December - Society of Critical Care Medicine

Volume 15 Issue 4
December 2015
Clinical Pharmacy and Pharmacology
Section Newsletter
Society of Critical Care Medicine
Section Officers
Chair
Ishaq Lat, PharmD
([email protected])
Past Chair
Karen McAllen, PharmD,
([email protected])
Chair-Elect
Russ Roberts, PharmD
(rroberts@tuftsmedicalcenter.
org)
Secretary/Treasurer
Amy Dzierba, PharmD
([email protected])
Members-at-Large
Seth Bauer, PharmD
([email protected])
Erin Frazee, PharmD
([email protected])
Ty Kiser, PharmD
([email protected])
MESSAGE FROM THE CHAIR
Ishaq Lat, PharmD, FCCM, FCCP, BCPS
“Do not let what you cannot do interfere with what you can do.”
—John Wooden
This newsletter marks my last message to the section. In what has
been an extremely productive year, I want to take this opportunity
to extend my appreciation to all the committee volunteers who
contributed their free time to section activities. Moreover, our
committee chairs and chair-elects have been key to the success of
section initiatives. Their time and dedication are the greatest
reasons for many of the initiatives available to section members.
Quite simply, nothing of substance would have been accomplished
without their commitment. Here is a brief listing of the committee
activities this past year that have benefited the membership:
 Providing a monthly online journal club
 Providing a monthly update of critical care pharmacotherapy
literature
 Publication of newsletter articles in relevant pharmacy
journals (e.g., Pharmacotherapy, American Journal of
Health-System Pharmacy)
 Development of the Congress Pre-Meeting Symposium
 Development of the Congress CPP Section Year-in-Review
session
 Coordination of the CPP Section Recruitment Exchange
 Development of resources and providing review to facilitate
member research endeavors
 Promotion of a multicenter project evaluating transitions of
care processes relating to critical care
 Fostering career development by pairing interested
members seeking mentorship with experienced mentors
 Offering a Visiting Clinical Professorship to promote critical
care pharmacy activities and exchange of ideas
 Facilitation of discounted membership for resident trainees
and recent graduates
 Archiving section member poster presentations
Your section officers have embodied the principle of servant
leadership. All through the past year, they have all sacrificed time
Volume 15 Issue 4
December 2015
from personal endeavors to serve on behalf of the membership.
Underlying all of the conversations at the Steering Committee level
has been the attitude of “How does this best serve our section and
future critical care pharmacists?” My deep gratitude to Russel
Roberts (chair-elect), Amy Dzierba (secretary/treasurer), Kerstin
McAllen (past chair), Seth Bauer (member-at-large), Erin Frazee
(member-at-large), Ty Kiser (member-at-large), Sandy Kane-Gill
(Council member), and Steve Martin (Council member).
There will be a number of activities in the coming years that will
broadly impact the section membership. If you are interested in
participating in committee activities, please feel free to contact
Russel ([email protected]) and join. Additionally,
anyone is welcome to attend CPP committee meetings at
Congress and to participate. Committee participation is open to all
members of the section and we are collectively better with an
engaged and active membership. It has been my privilege to serve
as your Chair for the past year. I look forward to meeting you at
Congress.
CPP COMMITTEE CORNER
Communications Committee
Simon Lam, PharmD, BCPS, FCCM (chair), and Joanna Stollings, PharmD, BCPS
(chair-elect)
The CPP Communications Committee members will be compiling highlights from some
of the educational sessions at the 2016 SCCM Congress. These will be published in
our April 2016 CPP newsletter. If anyone is interested in helping with educational
session summaries at Congress, please email Joanna Stollings at
[email protected].
Congratulations to all members of the CPP Section who had abstracts accepted for
presentation at the upcoming Congress. The abstracts information is included in this
issue of the newsletter. Our section has 275 accepted abstracts, with many abstracts
achieving high scores, warranting awards and recognition. Great job to all on your hard
work!
The production of this newsletter and other important CPP communication resources
does not happen without a dedicated team of volunteers. If you are interested in joining
the CPP Communications Committee or have any questions regarding the activities of
the committee, I encourage you to join us at the committee meeting on Tuesday,
Volume 15 Issue 4
December 2015
February 23, 2016 from 9:30 to 10:30 a.m. In addition, if you have any questions
regarding membership in the Communications Committee or contributions you would
like to make to the CPP Section newsletter, please email either Simon Lam at
[email protected] or Joanna Stollings at [email protected].
Education Committee
Jeffrey Gonzales, PharmD, BCPS, FCCM (chair), and Diana Mulherin, PharmD, BCPS
(chair-elect)
The CPP Education Committee continues to partner with the Society on several key
initiatives, including Journal Club, educational modules, and a toolkit for protocol
implementation. Journal Club continues to be held the third Friday of every month at
1:00 p.m. Central Time. We are pleased to announce a new Journal Club format, which
has expanded to include three speakers per session. If you would like to receive the
monthly notification and link to access the Journal Club sessions, please contact Karen
Berger at [email protected] or [email protected]. The CPP Education
Committee has also collaborated with the Graduate and Resident Education
Committee on three modules for Virtual Critical Care Rounds this year, including
antimicrobial therapy, anticoagulants, and delirium management. Additionally,
members of the Education Committee are evaluating the implementation of the Critical
Care Protocol Toolkit across multiple institutions. The Critical Care Protocol Toolkit can
be accessed at: http://www.sccm.org/News/Pages/New-LearnICU.org-ResourcesAvailable.aspx. These are just a few of the notable accomplishments made possible by
our members! If you would like to become involved in the Education Committee, please
contact Jeff Gonzales ([email protected]) or Diana Mulherin
([email protected]).
Membership Committee
Susan Hamblin, PharmD, BCPS (chair), and Serena Harris, PharmD, BCPS
(chair-elect)
Mentor-Mentee Program
The CPP Section mentor-mentee program connects pharmacists at all levels of
training, with the goal of furthering clinical practice, research, teaching skills, and
SCCM/CPP involvement. Mentees are able to identify their desired areas of mentorship
and are matched based on this information, along with practice area and years of
experience. This program has grown significantly during the past year, and we look
forward to continued growth. However, we continue to need mentors of all levels and
areas of practice. If you are interested in joining as a mentor or mentee, please contact
Susan Hamblin ([email protected]) or Serena Harris
([email protected]).
SCCM/CPP Congress Orientation for New Members and First-Time Attendees
The CPP Membership Committee would like to invite all new CPP members and firsttime Congress attendees to the new member orientation and reception. The orientation
will be Saturday, February 20, 2016 from 6:30 to 7:30 p.m., location TBD. This
Volume 15 Issue 4
December 2015
orientation is a good way for residents, new members, or experienced practitioners to
learn more about CPP involvement, navigating Congress, and the resources available
through the section. New members are able to learn more about the section leadership
and are provided with networking opportunities. We look forward to seeing all new
members and first-time attendees at the orientation! Thank you to Serena Harris and
Kristine Parbuoni for their planning efforts!
Membership Database
The membership database contains practice information, research interests, speaking
interests, and mentor-mentee program interest for the CPP Section. As we prepare for
2016 Congress, please take a few moments to complete the CPP Member Profile
Update link on the home page of the iRoom if you have not updated this information in
the past year.
Patient Safety Committee
Elizabeth Sinclair, PharmD, BCPS (chair), and Rachel Kruer, PharmD, BCPS
(chair-elect)
The Patient Safety Committee has chosen winners for the Innovations in Patient and
Medication Safety Award and the SCCM Excellence in Patient Safety Young
Pharmacist Investigator Award. The winners will be notified soon and will be
announced publicly at the CPP business meeting at Congress. We hope that interest
and enthusiasm for these awards continues to grow in the coming years. If you have
any feedback on the awards or the submission process, please send it to Elizabeth
Sinclair Goswami ([email protected]).
Members of the committee are continuing to work to organize safety-related research.
Current projects include a study on adverse drug event-related admissions to the ICU
and an evaluation of medication errors occurring during transitions of care. A section
subcommittee is also working on a review paper on alcohol withdrawal. If you have any
ideas related to patient safety research with which you would like to get involved, reach
out to Elizabeth Sinclair Goswami to learn how to join the Patient Safety Committee.
We are beginning to work on ideas to submit for patient safety-related programming for
2017 Congress. There are several ideas for proposals at this time, and we look forward
to seeing the final results of the committee’s work on this. If you have any ideas that
you would like the committee to consider, please reach out to Rachel Kruer
([email protected]).
Program Committee
Marilyn Bulloch, PharmD (chair), and Michaelia Cucci, PharmD (chair-elect)
The SCCM CPP Program Committee has been working hard throughout 2015. The
committee would like to think all of the members who have been instrumental in helping
us work toward all of our charges.
CPP Reception at 2016 Congress
Volume 15 Issue 4
December 2015
Our annual CPP reception at 2016 Congress will be held Saturday February 20, 2016
from 8:00 to 10:00 pm. We are still working with SCCM on the exact venue and will be
announcing the location soon. Please join us and take the opportunity to connect with
your colleagues and friends in critical care pharmacy.
Year-in-Review
The CPP Program Committee would like to encourage all CPP members to attend the
Pharmacy Year-in-Review at Congress on Monday, February 22, 2016 at 4:30 p.m.
The theme for the 2016 Year-in-Review will be Critical Care Pharmacy 2020: Looking
Forward to the Future of Critical Care Pharmacy. The topics will focus on areas of
interest identified by committee members as those that are shaping the future of critical
care pharmacy. Topics include: (1) “Emerging Infectious Diseases,” by Stephanie Bass;
(2) “Pharmacologic Considerations for Machines and Devices in Intensive Care,” by
Michaelia Dunn; and (3) “Advances in Nutrition Support,” by Diana Mulherin. The
program committee has matched each speaker with a mentor who has presented at the
Year-in-Review at past Congresses.
The committee has also started proactively planning for the 2017 Year-in-Review in
July and is in the process of developing the program.
Pre-Congress Update
Formally known as the Pre-Congress Symposium, the CPP will be hosting the PreCongress Update at Congress on Saturday February 20, 2016 at 5:00 p.m. The
location will be announced soon by SCCM. The event has undergone a name change
as mandated by SCCM, but will still follow the same format as in previous years. The
Eevolution of Critical Care Pharmacy to 2020 and Beyond. Topics include: (1) “Training
Models for Critical Care Pharmacy in 2020,” by Seth Bauer; (2) “The ICU Pharmacy
Matrix: Technology for Patient Care in 2020 and Beyond,” by Gourang Patel; and (3)
“Optimal Critical Care Services in 2020,” a roundtable discussion on the critical care
pharmacy position paper with Chris Paciullo, Mitch Daley, and Scot Bolesta.
Recruitment Exchange
The 3rd annual Recruitment Exchange will be held at the 2016 SCCM Congress in
Orlando, Florida. This is a no-charge, informal event that allows institutions with
available critical care pharmacy or related positions to meet with prospective
candidates. The committee asks all CPP members to share this information with their
institutions. The committee’s goal is to continue to increase participation by members
who seek quality candidates. This is a wonderful recruiting forum for institutions to
recruit top candidates.
The event will be held Sunday, February 21, 2016 from 11:30 a.m. to 12:30 p.m. The
location will be announced soon by SCCM. Potential candidates are not required to
register for the event. The committee does request that institutions send position
information to [email protected] by December 31, 2015. However,
onsite registrations will be welcome. All CPP members are encouraged to share
information regarding the event with institutions and potential candidates. Questions
about the event can be sent to [email protected] or
[email protected].
Volume 15 Issue 4
December 2015
Visiting Clinical Professor
The Visiting Clinical Professor (VCP) Program application deadline has been changed
to a rolling deadline. There are still some older applications circulating with the April
2015 deadline, but this has changed. Applications are included with this newsletter and
can also be found in the CPP iRoom by clicking on the Committee Documents link on
the left side of the page and then on the VCP folder. VCP is a great program, designed
to advance critical care pharmacy practice and teaching, particularly for those
establishing new services or adjusting current services in their institutions. Additional
information can be found within the VCP application or obtained by emailing Michaelia
Dunn at [email protected]
Research Committee
Mitch Daley, PharmD (Chair), and Heather Personett, PharmD (Chair-Elect)
The CPP Research Committee has exciting accomplishments to share. At the
upcoming SCCM Congress, our members will be presenting three abstract research
presentations on behalf of the CPP Section:

Hira Shafeeq and colleagues will present a survey on barriers to resident
publications from the resident perspective.

Joe Swanson and colleagues will present a survey on barriers to resident
publications from the preceptor perspective.

Abby Antigua and Stacy Voils will present an SCCM survey on the practices of
venous thromboembolism (VTE) prophylaxis in obese, critically ill patients.
In addition, we would like to congratulate Sarah Day, Megan Rech and the Critical Care
Pharmacotherapy Literature Update Team for the third consecutive publication of
“Major Publications in the Critical Care Pharmacotherapy Literature,” 2014 edition, in
American Journal of Health-System Pharmacy (AJHP). This review can be found
published ahead of print on the AJHP website.
In addition, we continue to consistently offer fundamental services and resources to
assist you in conducting research, including:

Recently updated funding opportunities (found in the iRoom under Non-SCCM
Funding)

Research consultation for any aspect of your study design (e-mail your inquiry to
[email protected])

Critical Care Pharmacotherapy Literature Updates (published on a monthly basis
in the iRoom under Committee Documents > Literature Updates)

Feedback for your manuscript or grant proposal (Contact Bryan Lizza
([email protected]) for more information or to submit a document for review)
Volume 15 Issue 4
December 2015
If you would like further information about any of these activities or would like to get
involved in the Research Committee, please contact Chair Mitch Daley
([email protected]) or Chair-Elect Heather Personett ([email protected]).
Pharmacotherapy Article
Tenecteplase for Thrombolysis in Pulmonary Embolism
John Hammer, PharmD, MBA, BCPS and Lauren A. Igneri, PharmD, BCPS
Pulmonary embolism (PE) is a common condition that has the potential to cause
significant morbidity and mortality. Patients with acute PE have varied clinical
presentations, ranging from asymptomatic to cardiac arrest. The bleeding risks
associated with thrombolytic therapy must be weighed against the benefits of lysing the
thromboembolism. Patients with acute PE and hemodynamic instability, referred to as
massive PE, or high-risk PE in the European guidelines, have a 30-day mortality
greater than 15% and should receive thrombolytic therapy unless contraindicated. The
use of thrombolytic therapy in patients with right ventricular dysfunction (RVD) or
cardiac injury without hemodynamic instability, referred to as submassive PE, which is
similar to the European category of intermediate-risk PE, is controversial because 30day mortality ranges from 3% to 15%. Guidelines do not recommend the use of
systemic thrombolytic therapy in low-risk PE without hemodynamic instability, RVD or
cardiac injury because 30-day mortality is generally less than 1% when treated with
standard anticoagulation.1, 2
Tenecteplase is a recombinant tissue plasminogen activator (tPA) that has been FDA
approved for the indication of acute myocardial infarction since 2000. 3 While currently
not approved in the United States for PE, tenecteplase has gained increased attention
following the 2014 PE Thrombolysis study (PEITHO), which is the largest, randomized
controlled trial to date evaluating the use of a thrombolytic for PE. Tenecteplase, like
alteplase, is a fibrin-specific tPA that preferentially activates plasminogen located on
the clot’s surface, forming plasmin that lyses the fibrin clot. Selectively activating
plasminogen bound to fibrin, rather than free plasminogen, could lead to greater
efficacy and safety than a nonselective tPA; however, this theory has never been
proven.3, 4 Tenecteplase is given as a weight-based dose ranging from 30 mg to 50 mg,
which is the same as the acute myocardial infarction dose given in the package insert.
The entire dose of tenecteplase is administered as an IV push over a period of 5
seconds, which is faster than the standard infusion time of any other thrombolytic for
PE.5
Literature review:
Although thrombolytic therapy has been proposed for use during cardiac arrest as a
means to treat both life-threatening PE and coronary thrombosis, current
cardiopulmonary resuscitation (CPR) guidelines recommend consideration of
adjunctive thrombolytic therapy only when cardiac arrest is secondary to known or
suspected PE.6 This recommendation is made based on the findings from two large,
prospective clinical trials that failed to show benefit in outcomes when thrombolytic
Volume 15 Issue 4
December 2015
therapy was administered during CPR.7, 8 Bottiger et al performed a double-blind,
multicenter trial in Europe in which 1,050 patients with witnessed out-of-hospital cardiac
arrests were randomized to receive weight-based tenecteplase or placebo during
prehospital CPR. Treatment with open-label thrombolytic therapy was permitted if PE
was suspected. The trial was terminated early after a futility analysis showed nearly
identical rates of survival between groups. No significant difference in 30-day survival
was seen in the tenecteplase (14.7%) versus placebo (17.0%) groups (RR of survival
0.87; 95% CI, 0.65 to 1.15; p = 0.36) or with any secondary endpoints including return
of spontaneous circulation, hospital admission, 24-hour survival, survival to hospital
discharge, or neurologic outcome.7 These findings are consistent with those of a
prospective study that randomized 233 patients to receive either alteplase (100 mg IV
over 15 min) or placebo if unresponsive to one minute of standard therapy for out-ofhospital cardiac arrest with pulseless electrical activity.8 Enrollment was stopped early
in the aforementioned tenecteplase study; it is possible that no difference in outcomes
was found because the study was underpowered. However, those who received
tenecteplase had a significant increase in intracranial hemorrhage (ICH) compared to
placebo (2.7% vs. 0.4%), (RR of ICH 6.95; 95% CI, 1.59 to 30.41; p = 0.006; number
needed to harm [NNH] = 44). Low enrollment of patients with suspected PE (6.0% in
tenecteplase group, 11.0% in placebo group) ultimately limits the generalizability of the
findings to this population.7 Thus, thrombolysis may be attempted when all other
standard resuscitative measures have failed during cardiac arrest if there is
confirmation of, or high suspicion for, PE.
In patients without a high risk of bleeding, systemically administered thrombolytic
therapy is suggested for acute PE associated with hypotension (e.g., systolic blood
pressure [SBP] < 90 mm Hg) or when the clinical course after starting anticoagulation
suggests a high risk of developing hypotension. These recommendations are based on
low-level evidence (Grade 2C) from alteplase, streptokinase, urokinase, reteplase, and
desmoteplase administration in these populations.9 In a prospective study, eight
patients with massive PE were randomized to receive 1,500,000 IU streptokinase, IV,
over a period of 1 hour followed by unfractionated heparin (UFH) (n = 4) or UFH alone
(n = 4). The trial was terminated after all patients in the UFH-only group died within 1 to
3 hours of randomization compared to 0 deaths in the streptokinase-plus-UFH group (p
= 0.02).10 Although prospective, controlled trials assessing tenecteplase for the
management of massive PE without cardiac arrest are lacking, numerous case reports
and cohort studies have detailed good patient outcomes with the use of a weight-based
bolus in conjunction with UFH or low-molecular-weight heparin (LMWH).11, 12 Due to the
high mortality associated with massive PE without thrombolytic intervention and the
pharmacokinetic advantages of tenecteplase, off-label use of tenecteplase may be
considered for this indication.
Tenecteplase has been studied in patients presenting with submassive PE causing
significant RVD. TIPES, a phase II, double-blind, multicenter study in Italy, randomized
58 patients with PE, SBP > 100 mm Hg, and RVD to weight-based tenecteplase or
placebo with UFH. The study was terminated early in order to have results available
before the PEITHO international study began at the end of 2006. The primary endpoint
was reduction in RVD 24 hours after randomization. The mean absolute reduction in
right/left ventricle end-diastolic dimension (R/LV EDD) at 24 hours was 0.31±0.08 in the
Volume 15 Issue 4
December 2015
tenecteplase group versus 0.10±0.07 in the placebo group (p = 0.04). No significant
difference in R/LV EDD was seen between groups at day 7.13 Limitations of this study
include the use of a surrogate endpoint as a marker of clinical efficacy, although
normotensive patients with RVD are known to have a higher probability of progressing
to shock.14 Two patients receiving tenecteplase and 1 receiving placebo developed
major, nonfatal bleeding, and 13 patients receiving tenecteplase and 1 receiving
placebo developed minor bleeding. The small sample size may limit interpretation of
major bleeding outcomes with tenecteplase in this population.
A similar population was evaluated in the multicenter, double-blinded, randomized
controlled study, Tenecteplase or Placebo: Cardiopulmonary Outcomes at Three
Months (TOPCOAT), in the United States. Eighty-three patients with SBP ≥ 90 mm Hg
and evidence of RVD were randomized to receive weight-based tenecteplase or
placebo in addition to LMWH for management of PE. Primary composite endpoint
included (i) death, circulatory shock requiring vasopressor infusion, need for intubation,
and major bleeding within 5 days, or (ii) recurrent PE, poor functional capacity, or an
SF-36 Physical Component Summary score < 30 at 90-day follow-up. Three patients in
the placebo group developed an adverse outcome within 5 days (1 cardiac arrest
secondary to PE; 2 required intubation, vasopressor support, and catheter-directed
thrombectomy) and 1 patient in the tenecteplase group died secondary to ICH. At 90
days, the composite endpoint was met in 37% of the placebo group versus 15% of the
tenecteplase group (p = 0.017).15 Quality of life (QOL) was included in the primary
endpoint because patients with PE are known to experience a poor functional capacity
for up to three months after initiation of anticoagulation.16 The significant difference
between groups was primarily driven by functional capacity and QOL at 90 days rather
than acute outcomes within 5 days of randomization. Therefore, hemodynamically
stable patients with RVD may report improved QOL if they receive fibrinolysis as part of
PE management.
PEITHO was an international, multicenter, double-blind trial that randomized 1,006
patients with PE, RVD, and elevated troponin to either weight-based tenecteplase or
placebo with UFH. The primary endpoint of death or hemodynamic compromise
occurring within 7 days of randomization was seen in 2.6% of the tenecteplase group
versus 5.6% of the placebo group (OR 0.44; 95% CI, 0.23 to 0.87; p = 0.02; NNT = 34).
Of note, death within the first 7 days and first 30 days was not statistically different
between groups, indicating that the difference in the primary outcome was due to
hemodynamic decompensation. Patients who received tenecteplase experienced more
major extracranial bleeding within 7 days versus placebo (6.3% vs. 1.2%), (OR 5.55;
95% CI, 2.3 to 13.39; p < 0.001; NNH = 20) and stroke (2.4% vs. 0.2%), (OR 12.10;
95% CI, 1.57 to 93.39; p = 0.003; NNH = 46).5 Long-term results from patient follow-up
180 days after study randomization are forthcoming.17 Although patients with PE and
evidence of RVD may have improved hemodynamics from tenecteplase administration,
an increased risk of major bleeding, including ICH, was identified. This is in contrast to
the findings of a prospective, controlled study that randomized 256 hemodynamically
stable patients with PE and RVD to alteplase, 100 mg (10 mg IV bolus, followed by 90
mg IV over 2 hours) plus UFH versus UFH only. No significant difference in mortality or
major bleeding was seen between groups, but the need for escalation of treatment was
significantly lower in patients who received alteplase.18 It is unclear why differences in
Volume 15 Issue 4
December 2015
bleeding outcomes were seen when evaluating these two studies, but notably, nearly
one-third of patients in the PEITHO study received a dose of LMWH or fondaparinux
before randomization. Another difference was the added inclusion criteria of elevated
troponin as part of the RVD definition in PEITHO, which may indicate that a higher-risk
population was studied. Based on current literature, tenecteplase may be considered
for thrombolysis in hemodynamically stable patients with PE and significant RVD who
are at high risk for developing hypotension and at low risk for bleeding.
There is a paucity of high-quality, prospective, randomized controlled trials comparing
tenecteplase to other thrombolytics for PE. Additionally, there are no prospective
studies evaluating the use of tenecteplase in massive PE with the exception of those
who present in cardiac arrest. It is unlikely that a future randomized, controlled trial
comparing thrombolysis plus anticoagulation to anticoagulation alone will be conducted
in massive PE. This study design would be unethical based on the findings from the
previously discussed streptokinase study and expert opinion from guidelines
recommending thrombolytics in massive PE unless contraindications are present. 1, 9, 10
Despite the lack of prospective data demonstrating benefit in clinical outcomes, it is
reasonable to generalize the effectiveness of tenecteplase with submassive PE to
massive PE. Tenecteplase is a fibrin-specific thrombolytic that has the advantage of
faster and more convenient administration compared to other thrombolytics since it is
given as an IV push. It has not yet been shown whether rapid administration leads to
better clinical outcomes. Currently, there is insufficient data to guide the decision to
prescribe tenecteplase over alternative thrombolytics, including alteplase, which has
FDA approval for use in PE. Given the administration advantages compared to other
thrombolytics, tenecteplase may be a reasonable alternative for the management of
PE.
References:
1. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and
management of acute pulmonary embolism: the Task Force for the Diagnosis and
Management of Acute Pulmonary Embolism of the European Society of Cardiology
(ESC). Eur Heart J. 2008 Sep;29(18):2276-2315.
2. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive
pulmonary embolism, iliofemoral deep vein thrombosis, and chronic
thromboembolic pulmonary hypertension: a scientific statement from the American
Heart Association. Circulation. 2011 Apr 26;123(16):1788-1830.
3. TNKase (tenecteplase) [package insert]. South San Francisco, CA: Genentech, Inc;
2000 June. Revised 2011 May.
4. Todd JL, Tapson VF. Thrombolytic therapy for acute pulmonary embolism: a critical
appraisal. Chest. 2009 May;135(5):1321-1329.
5. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk
pulmonary embolism. N Engl J Med. 2014 Apr 10;370(15):1402-1411.
6. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life
support: 2010 American Heart Association Guidelines for Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care. Circulation. 2010 Nov 2;122(18
Suppl 3):S729-767.
Volume 15 Issue 4
December 2015
7. Bottiger BW, Arntz HR, Chamberlain DA, et al. Thrombolysis during resuscitation for
out-of-hospital cardiac arrest. N Engl J Med. 2008 Dec 18;359(25):2651-2662.
8. Abu-Laban RB, Christenson JM, Innes GD, et al. Tissue plasminogen activator in
cardiac arrest with pulseless electrical activity. N Engl J Med. 2002 May
16;346(20):1522-1528.
9. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease:
antithrombotic therapy and prevention of thrombosis, 9th ed: American College of
Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012
Feb;141(2 Suppl):e419S-e494S.
10. Jerjes-Sanchez C, Ramírez-Rivera A, de Lourdes García M, et al. Streptokinase
and heparin versus heparin alone in massive pulmonary embolism: a randomized
controlled trial. J Thromb Thrombolysis. 1995;2(3):227-229.
11. Caldicott D, Parasivam S, Harding J, Edwards N, Bochner F. Tenecteplase for
massive pulmonary embolus. Resuscitation. 2002 Nov;55(2):211-213.
12. Shukla AN, Thakkar B, Jayaram AA, Madan TH, Gandhi GD. Efficacy and safety of
tenecteplase in pulmonary embolism. J Thromb Thrombolysis. 2014 Jul;38(1):2429.
13. Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle
dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb
Res. 2010 Mar;125(3):e82-e86.
14. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with
acute pulmonary embolism, normal blood pressure, and echocardiographic right
ventricular dysfunction. Circulation. 2000 Jun 20;101(24):2817-2822.
15. Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary
embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months:
multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost.
2014 Apr;12(4):459-468.
16. Kline JA, Hernandez J, Hogg MM, et al. Rationale and methodology for a
multicentre randomised trial of fibrinolysis for pulmonary embolism that includes
quality of life outcomes. Emerg Med Australas. 2013 Dec;25(6):515-526.
17. Konstantinides S, Meyer G, Lang I, et al. Single-bolus tenecteplase plus heparin
compared with heparin alone for normotensive patients with acute pulmonary
embolism who have evidence of right ventricular dysfunction and myocardial injury:
rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am
Heart J. 2012 Jan;163(1):33-38.e1.
18. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with
heparin alone in patients with submassive pulmonary embolism. N Engl J Med.
2002 Oct 10;347(15):1143-1150.
Member Spotlight: Suprat Saely Wilson, PharmD, BCPS
by Jessica Jones, PharmD, BCPS
Suprat Saely Wilson, PharmD, BCPS, is the pharmacy
coordinator and a clinical specialist for emergency
medicine services at Detroit Receiving Hospital
(DRH)/Detroit Medical Center (DMC). She is also the
director of the DMC PGY2 Emergency Medicine
Volume 15 Issue 4
December 2015
Pharmacy Residency Program. The Emergency
Department (ED) at Detroit Receiving Hospital is a 92bed, level I trauma center with more than 110,000 patient
visits each year. The Department of Pharmacy Services is
an integral part of the emergency medicine (EM)
multidisciplinary team, providing 24-hour clinical services,
including medical and trauma resuscitation. Additionally,
Dr. Wilson serves as adjunct clinical faculty for University
of Michigan College of Pharmacy, Wayne State University
Eugene Applebaum College of Pharmacy and Health
Sciences, and the Raabe College of Pharmacy at Ohio
Northern University.
Dr. Wilson received her doctor of pharmacy degree from the University of Michigan in
2008. She completed her PGY1 and PGY2 residencies at the Detroit Medical Center,
PGY1 at Sinai-Grace Hospital and PGY2 in emergency medicine at Detroit Receiving
Hospital. After completion of her residency, Dr. Wilson became a clinical specialist in
the DRH ED in 2010, and expanded her role to residency director in 2012 and
pharmacy coordinator in 2014. She continues to practice as a clinical specialist, writing
policies and protocols for pharmacy emergency medicine services. Dr. Wilson is
passionate about pharmacy integration into emergency medicine services and ensuring
excellent education of residents and students. She precepts both students and
residents on clinical rotations year-round, and also provides didactic lectures and
facilitates several courses. She received the American Society of Health-System
Pharmacists (ASHP) New Preceptor Award in 2015. Dr. Wilson is the founding editor of
the DMC pharmacy newsletter, The Receptor, to which residents contribute. She also
plans the annual programming for the Michigan Society of Health-System Pharmacists
meetings, including the Michigan Pharmacists Association Annual Convention &
Exposition, residency meetings, and the DMC Annual Infectious Diseases and Critical
Care Symposium.
In addition to her local and regional committee involvement, Dr. Wilson is an active
member in several national organizations, including the American College of Clinical
Pharmacy (ACCP), the ASHP, and the Society of Critical Care Medicine (SCCM). She
is currently the member-at-large for the Emergency Medicine Section of SCCM, as well
as a member of the Clinical Pharmacy and Pharmacology (CPP) Patient Safety and
Education Committee. She has served on the Programming Committee, Travel Award
Committee, Code Committee, and Media Committee for the American College of
Clinical Pharmacy (ACCP) Emergency Medicine Practice and Research Network, as
well as serving on the ASHP section advisory groups on emergency care and
education. Additionally, Dr. Wilson is an ASHP guest surveyor for emergency medicine
residency. As evidenced by her extensive involvement, Dr. Wilson is a well-respected
clinician who contributes greatly to the profession of pharmacy.
Research Pearl
Formulating Research Questions and Hypotheses: Control of Confounding to
Reduce Bias in Research
Volume 15 Issue 4
December 2015
by Todd Miano, PharmD, MSCE
Confounding is a potential source of bias in virtually every research study. Defined as a
confusion of effects, confounding arises when the effect of a risk factor is mistaken for
the effect of the exposure of interest.1 Confounding is created when risk factors are
imbalanced across treatment groups. For example, consider a study that examines the
rate of acute kidney injury (AKI) in patients treated with vancomycin monotherapy
compared to vancomycin plus piperacillin/tazobactam (VPT). In this scenario, you
might expect higher aminoglycoside use in the VPT group, because those patients may
have an indication for broad gram-negative coverage. In this scenario, aminoglycoside
exposure is a confounding variable—any difference in AKI rate between groups may
not be the result of piperacillin/tazobactam exposure, but instead the result of more
frequent aminoglycoside use in the VPT group. If we want to accurately measure the
effect of VPT combination therapy, we must control for the effect of aminoglycoside
exposure.
Control of confounding can be achieved during the design and data analysis stages of
research. Study design features that control confounding include randomization,
restriction, and matching.1 The gold standard for control of confounding is
randomization. Indeed, removal of confounding is the sole benefit of randomization. 1
Random treatment allocation ensures balance of both measured and unmeasured risk
factors across treatment groups, removing potential sources of confounding. In many
clinical situations, however, randomization may be unfeasible or unethical. Thus,
alternative methods for confounding control are often needed.
Restriction refers to the exclusion of patients with a given risk factor. If no patients in
the population have a given risk factor, researchers can be sure that confounding from
that risk factor is removed. Matching involves finding control patients that match the
exposed patients on particular risk factors. In the AKI example above, researchers
could match VPT patients to vancomycin patients on age, presence of hypotension,
and baseline serum creatinine concentration. Matching on these factors ensures
balance in those variables across groups, thereby removing confounding.
The most common data analysis technique to control confounding is multivariable
modeling (e.g., multiple linear regression, multiple logistic regression, and proportional
hazards regression).2 Confounding is controlled by simultaneously including important
risk factors with the exposure of interest in the multivariable model. This modeling
isolates the effect of the exposure while holding all risk factors constant. Another
popular approach is the use of propensity scores. The propensity score for an
individual is the probability of being treated based on the individual’s background
characteristics and risk factors.3 Confounding can be removed by matching on the
propensity score. In our example, each VPT patient would be matched with a
vancomycin patient who has a similar propensity score. Matching on treatment
probability balances all risk factors included in the propensity score model, which can
be thought of as mimicking the randomization process.3 Unlike randomization,
however, propensity score analysis can control confounding only from measured risk
factors.
Volume 15 Issue 4
December 2015
References:
1. Rothman KJ. Epidemiology: An Introduction. 2nd ed. New York, NY: Oxford
University Press; 2012.
2. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann
Intern Med. 2003 Apr 15;138(8):644-650.
3. Rosenbaum PR, Rubin DB. The central role of the propensity score in
observational studies for causal effects. Biometrika. 1983;70(1):41-55.
CPP-Specific Itinerary at Congress
Saturday, February 20, 2016
CPP Section Pre-Congress Update
5:00 p.m. – 6:30 p.m.
CPP Section New Members and First Congress Attendees Orientation
6:30 p.m. – 7:30 p.m.
CPP Section Reception
8:00 p.m. – 10:00 p.m.
Sunday, February 21, 2016
CPP Section Recruitment Exchange Meeting
11:30 a.m. – 12:30 p.m.
CPP Section Program Committee Meeting
4:30 p.m. – 5:30 p.m.
Monday, February 22, 2016
CPP Section Education Committee Meeting
9:00 a.m. – 10:00 a.m.
CPP Section Patient Safety Committee Meeting
10:00 a.m. – 11:00 a.m.
CPP Section Research Committee Meeting
11:00 a.m. – 12:00 p.m.
CPP Section Membership Committee Meeting
12:00 p.m. – 1:00 p.m.
Tuesday, February 23, 2016
CPP Section Communications Committee Meeting
9:30 a.m. – 10:30 a.m.
CPP Business Meeting
Volume 15 Issue 4
December 2015
12:30 p.m. – 2:00 p.m.
45th Annual Critical Care Congress
Clinical Pharmacy and Pharmacology Section Meeting Guide
February 20-24, 2016
**Please check the Program and Exhibition guide at Congress for locations and the most up-to-date schedule.**
Friday, February 19, 2016 (Pre-Congress Educational Session)
8:00 AM - 9:30 AM
Current Concepts in Adult Critical Care –
Day 1
Early Recognition of Unusual Medication
Emergencies and Drug Shortages
Current Concepts in Pediatric Critical Care
– Day 1
Pharmacologic Optimization in Unique
Circumstances
Panel Discussion
Critical Care Pharmacy Preparatory Review
and Recertification Course – Day 1
Shock Syndromes and Sepsis
9:30 AM - 10:15 AM
Supportive and Preventive Medicine
10:30 AM - 11:30 AM
Practice Management: Medication Safety and
Protocol Development
11:30 AM - 12:30 PM
1:30 PM - 3:00 PM
Cardiovascular Critical Care
Fluids, Electrolytes, Acid-Base Disorders and
Nutrition Support
3:00 PM - 3:45 PM
Principles of Estimating Renal Clearance,
Acute Kidney Injury, and Renal Replacement
in the Critically Ill Patient
Pulmonary Disorders
8:00 AM - 5:00 PM
11:15 AM - 12:00 PM
8:00 AM - 5:00 PM
8:35 AM - 9:05 AM
9:40 AM - 10:15 AM
8:00 AM - 5:30 PM
4:00 PM - 5:30 PM
Saturday, February 20, 2016 (Pre-Congress Educational Session)
8:00 AM - 5:30 PM
Critical Care Pharmacy Preparatory Review
8:00 AM - 9:30 AM
and Recertification Course – Day 2
Neurocritical Care
Mitchell J. Daley, PharmD, BCPS
Jennifer L. Morris, PharmD, BCPS
Jennifer L. Morris, PharmD, BCPS
Moderator: Amy Dzierba,
PharmD, FCCM, BCPS
Ishaq Lat, PharmD, FCCM, FCCP,
BCPS
Seth R. Bauer, PharmD, FCCM,
BCPS
Amy L. Dzierba, PharmD, FCCM,
BCPS
Lisa G. Hall Zimmerman, PharmD,
FCCM, BCPS, BCNSP
Henry Cohen, BS, MS, PharmD,
FCCM, BCPP, CGP
Erik E. Abel, PharmD, BCPS
Roland N. Dickerson, PharmD,
FCCM, FCCP, FASHP, FASPEN,
BCNSP
Michael L. Bentley, PharmD, FCCM
Ishaq Lat, PharmD, FCCM, FCCP,
BCPS
Amy L Dzierba, PharmD, FCCM,
BCPS
Moderator: Simon W. Lam,
PharmD, BCPS
Gretchen M. Brophy, PharmD,
FCCP, FCCM, BCPS
Aaron M. Cook, PharmD, BCPS
Volume 15 Issue 4
9:30 AM - 10:30 AM
10:45 AM - 11:45 AM
11:45 AM - 12:45 PM
1:45 PM - 2:30 PM
Sedation, Pain, Analgesia, Delirium, and
Neuromuscular Blockers
Research Design and Literature Evaluation
2:30 PM - 3:15 PM
Acute Cardiac Care
Hepatic Failure/Gastrointestinal/Endocrine
Emergencies
Toxicology
3:30 PM - 4:30 PM
4:30 PM - 5:30 PM
Infectious Diseases I
Infectious Diseases II
December 2015
Kimberly L. Varney, PharmD,
BCPS
Ishaq Lat, PharmD, FCCM, FCCP,
BCPS
Scott T. Benken, PharmD, BCPS
Seth R. Bauer, PharmD, FCCM,
BCPS
Steven Pass, PharmD, FCCP,
FCCM, FASHP, BCPS
Eric W. Mueller, PharmD, FCCM,
FCCP
Simon W. Lam, PharmD, BCPS
Sunday, February 21, 2016
10:30 AM - 11:30 AM Resuscitation
11:30 AM - 12:30 PM
11:30 AM - 12:30PM
Fluid Controversies
Albumin: Has Anything Changed Since the
SAFE Study?
De-resuscitation: Reversal When the Fluid
Comes Back
Diuresis in Deresuscitation
Ketamine Use in the ICU: Re-Emergence of
Special K
Antiepileptic Uses of Ketamine
Pros and Cons of Ketamine Use for ICU
Sedation
Susan E. Hamblin, PharmD, BCPS
Michael L. Bentley, PharmD, FCCM
Hira Shafeeq, PharmD, BCPS
Chris A. Droege, PharmD
Monday, February 22, 2016
6:00 AM - 8:00 AM
Improving
10:00 AM - 11:00 AM
10:00 AM - 12:00 PM
10:00 AM - 12:00 PM
Clinical Outcomes and
Pathogen-Directed Therapy for Serious
Bacterial Infections in the Critical Care
Setting
New and Emerging Therapeutic Options for
Treatment
Bench-Pressing in the ICU: Which
Vasopressor Agent Should I Choose for
My Patient?
Which Box Does Your Patient Fit In? The
Method Behind the Madness
Controversies in Neurocritical Care
Seizure Prophylaxis
Conversing with the Experts: Panel
Discussion
The Difficult Task of Treating MultidrugResistant Acinetobacter baumannii
An Old Drug Revisited: The Role of Colistin
Emerging Antibiotic Treatments
Jason M. Pogue, PharmD
Gourang P. Patel, PharmD, MSc,
BCPS
Gretchen M. Brophy, PharmD,
FCCP, FCCM, BCPS
Gretchen M. Brophy, PharmD,
FCCP, FCCM, BCPS
Lama H. Nazer, PharmD, BCPS
Steven Pass, PharmD, FCCP,
FCCM, FASHP, BCPS
Volume 15 Issue 4
10:00 AM - 12:00 PM
10:00 AM - 12:00 PM
3:15 PM - 4:15 PM
3:15 PM - 4:15 PM
4:30 PM - 5:30 PM
4:30 PM - 5:30 PM
New American College of Critical Care
Medicine Guidelines
Guidelines for Stress Ulcer Prophylaxis in
Adult Critically Ill Patients
Pediatric Pulmonary Hypertension: The
Changing Landscape
Medications and Novel Therapies for Shortand Long-Term Management
Precision Pharmacodelivery in the PICU:
Role of Kinetics Analysis and Modeling
Pathophysiologic Mechanisms of Variability to
Drug Response in Critical Ill Conditions
Pharmacokinetics and Pharmacodynamics
Modeling in Pediatrics
Assessing and Reversing Coagulopathy in
the ICU
Reversal of Novel Anticoagulants
A Ninja in the ICU: Novel Methods for the
Prevention of Drug-Associated Acute
Kidney Injury
Risk Factors and Predictors of DrugAssociated AKI
Striving for Early Detection of DrugAssociated AKI
Year in Review: Clinical Pharmacology and
Pharmacy
Emerging Infectious Diseases
Pharmacologic Considerations for Machines
and Devices in Intensive Care
Advances in Nutrition Support
December 2015
Henry Cohen, BS, MS, PharmD,
FCCM, BCPP, CGP
Eric E. Abel, PharmD, BCPS
Moderator: Elizabeth Farrington,
PharmD, FCCM, FCCP, FPPAG,
BCPS
Elizabeth Farrington, PharmD,
FCCM, FCCP, FPPAG, BCPS
Jennifer L. Morris, PharmD, BCPS
Moderator: William Dager,
PharmD, FCCM, FCCP, FCSHP,
BCPS
Mitchell J. Daley, PharmD, BCPS
Moderator: Sandra L Kane-Gill,
PharmD, MSc, FCCM, FCCP
Brian L. Erstad, PharmD, BCPS,
MCCM
Sandra L. Kane-Gill, PharmD, MSc,
FCCM, FCCP
Moderator: Ishaq Lat, PharmD,
FCCM, FCCP, BCPS
Stephanie Bass, PharmD
Michaelia Dunn, PharmD, BCPS
Diana Wells Mulherin, PharmD,
BCPS
Tuesday, February 23, 2016
10:00 AM - 12:00 PM Advancing
11:00 AM - 12:00 PM
2:00 PM - 2:45 PM
3:15 PM - 4:15 PM
Nutrition Therapies in the ICU
Malnutrition, Metabolomics, Muscles and
Metabolism: Getting the Most out of Nutrition
Therapy
Training the Next Generation of Critical
Care Practitioners: State of the (Critical
Care) Union
Pharmacist Perspective
Plenary Session: Value-Based Medicine:
Dollars and Sense
Aerosolized Antibiotics in the ICU: Where
Do They Fit?
Brian L. Erstad, PharmD, BCPS,
MCCM
Michael W. Sirimaturos, PharmD,
BCNSP
Brian L. Erstad, PharmD, BCPS,
MCCM
Volume 15 Issue 4
4:30 PM - 5:30 PM
December 2015
Bioavailability: Pharmacokinetics of
Aerosolized Antibiotics
It’s Hot! Not Every Fever Is an Infection
Eric W. Mueller, PharmD, FCCM,
FCCP
Moderator: Gretchen M Brophy,
PharmD, FCCP, FCCM, BCPS
Aaron M. Cook, PharmD, BCPS
Neuroleptic Malignant Syndrome
Wednesday, February 24, 2016
9:30 AM - 10:30 AM
This Is Jeopardy:
Questions and Answers
with Anticoagulation Reversal
Bleeding Jeopardy
10:30 AM - 11:30 AM
Immunomodulation in the Critically Ill
10:30 AM - 11:30 AM
Management of the Acute Care Surgical
Patient
When to Stop the Antibiotics: The Feces Are
Everywhere
Moderator: Jeffrey Barletta,
PharmD, FCCM
William Dager, PharmD, FCCM.
FCCP, FCSHP, BCPS
Gourang P. Patel, PharmD, MSc,
BCPS
Moderator: Gretchen M Brophy,
PharmD, FCCP, FCCM, BCPS
Simon W. Lam, PharmD, BCPS
Clinical Pharmacy and Pharmacology Section Member Abstracts at 2016 Congress
Abstract
Number
Title
20
Four-Factor Prothrombin Complex Concentrate for
Life-Threatening Bleeds or Emergent Surgery
EEG Suppression Ratio 6 Hours After Cardiac Arrest
- Accurate Biomarker of Severity of Brain Injury
Apoptotic Pathway Mediates the Neuroprotective
Effect of IRL-1620 in Focal Cerebral Ischemia
Levetiracetam is as effective as phenytoin for status
epilepticus with less adverse events in the ED
30
Pain Assessment in Critically Ill Patients with
Delirium: Self-reported Pain versus Behavioral Pain
4
15
19
42
43
45
49
52
53
Telecritical care implementation in community
hospitals decreased ICU and hospital mortality
Desaturation during tracheal intubations in PICUs is
pervasive and associated with adverse outcomes
Influence of withholding pharmacologic prophylaxis
doses on venous thromboembolism occurrence
Outcomes of hyperoncotic albumin exposure and
risk of ICU organ dysfunction in shock
Long term outcome of patients with liver cirrhosis
admitted to a general intensive care unit
Safety and effectiveness of weight-based activated
PCC for warfarin-induced life-threatening bleeding
CPP Authors
Christine Lesch, PharmD
Jonathan Sin, PharmD
Richard R. Riker, MD, FCCM
Anil Gulati, MD, PhD
Jaclyn O’Connor, BCPS, PharmD
Suprat Saely Wilson BCPS, PharmD,
PharmD
Rima Bouajram PharmD
Jeremiah J. Duby, BCPS, PharmD
Erin Nagle, PharmD
Sean D. Firth, MPH, PhD
Pradip P. Kamat, MBA, MD
Seth R. Bauer, BCPS, PharmD, FCCM
Belinda L. Udeh, PhD, MPH
Matthew R. Wanek, BCPS, PharmD
John Kinsella, MD
Suprat Saely Wilson BCPS, PharmD
Volume 15 Issue 4
Abstract
Number
54
57
58
71
75
79
82
90
98
100
104
111
120
123
130
132
134
144
145
151
December 2015
Title
Daily vancomycin dose requirements as a
continuous infusion in obese vs. non-obese SICU
patients
Reducing time to antibiotic administration in septic
SICU patients: pre and post intervention
A Feasibility Trial to Detect Sepsis in the ED Based
Upon Blood Monocyte Volume Variability
Cardiac Hemodynamic Changes During Weaning
From Mechanical Ventilation Using NICOM: Pilot
Study
Quetiapine-associated QTc prolongation in cardiac
surgery patients with ICU delirium
Standard versus low dose alteplase infusion for
treatment of acute pulmonary embolism
Mortality and Incidence of Acute Adverse Neurologic
Events in the Cardiac Intensive Care Unit
Pharmacologic Treatment of ICU Delirium is Not
Associated with Increased Development of
Arrhythmias
Does DDAVP increase renal insufficiency and
prolong mechanical ventilation in cardiac surgery?
Impact of intraoperative continuous vs. intermittent
cefazolin therapy on the incidence of SSIs
Recombinant Activated Factor VII Use in Cardiac
Surgery – A Single Center Experience
Survey of Analgesia, Sedation, and Shivering
Practice During Targeted Temperature Management
Efficiency of Simple Hemofiltration with Concurrent
Veno-Arterial Extra-Corporeal Life Support
Predictors of response to insulin, glucagon, and lipid
emulsion in antihypertensive overdose
The Incidence Of Subglottic Stenosis Following
Cardiac Surgery In Infants And Children
Efficacy and Safety of Milrinone versus Dobutamine
in Cardiogenic Shock
Intravenous Chlorothiazide in Acute Heart Failure
Refractory to Loop Diuresis and Adjunct Metolazone
Knowledge Capture techniques to design a score of
overall physiological state in Critical Illness
Development of a Quantitative Clinical Instability
Score weighted for the degree of support required
Sensitivity and Specificity of a Pediatric Early
Warning System Using Data-Driven Vital Signs
CPP Authors
Hsin Lin, PharmD
Hsin Lin, PharmD
Keri J. Bicking, BCPS, PharmD, BCNSP
Antonio Saad, MD
William D. Cahoon Jr, PharmD
Amanda Kroll Duman, BCPS, PharmD
Nicole Harger
Lukas Martin, PharmD
Yuliya A. Domnina, MD
Claire V. Murphy, PharmD
John Blackburn, MD
Jessica R. Crow, BCPS, PharmD
Stephanie L. Davis, BCPS
Bethany Shoulders
Mindee Sue Hite, PharmD
Kevin M. Silinskie, PharmD
Cassandra J. Bellamy, PharmD
Christina L. Candeloro, PharmD
Robert Nietupski, BCPS, PharmD
Julia Weiner, PharmD
Jeffrey J. Cies, PharmD, MPH, BCPS
Nicole Harger
Kristen E. Hillebrand, PharmD
Prashant Purohit, MD, MD
Diana Esaian, BCPS, PharmD
Caitlin M. Aberle, BCPS, PharmD
Tyler Lewis, PharmD
John Papadopoulos, BS, PharmD, FCCM
Maria Cardinale, PharmD BCPS
John Kinsella, MD
John Kinsella, MD
Natalie Michelle Pageler, MD, MEd
Volume 15 Issue 4
Abstract
Number
165
December 2015
Title
Novel Application of Tele-ICU Presence to Support
Rapid Response Calls in a Community Hospital
Adverse drug reactions during therapeutic
hypothermia after cardiac arrest
173
187
195
200
211
219
221
An Evaluation of Sedation and Neurologic Outcome
in Therapeutic Hypothermia Following Cardiac
Arrest
Implementing a competency program to improve
pharmacist participation in code blue response
The Effects of Miniaturized Chest Compressor on
Quality and Outcome of CPR in ICU Patients
Neuromuscular blockers for shivering prevention
during therapeutic hypothermia post cardiac arrest
The Dollar $ign Project: an innovative drug costawareness tool for medical providers
Critical Care Pharmacy Resident Research
Publication: Residency Directors Perceptions and
Practices.
Critical Care Pharmacy Resident Research Project
Publication: Practices and Perceptions of Graduates
225
234
238
248
250
A degree course in critical care for undergraduate
medical students - the student view
Effect of simulation training on intubation practices
of fellows in a training program
The FOAM effect: use of smartphone-created videos
to standardize resident orientation and education
Evaluation of Pharmacy-Nursing Collaborative
Education on the Critical Care Pain Observational
Tool
Management of diabetic ketoacidosis/hyperglycemic
hyperosmolar state in patients on hemodialysis
262
264
Stress dose hydrocortisone use in pediatric septic
shock varies and is associated with poor outcomes
CPP Authors
Belinda L. Udeh, PhD, MPH
Amy L. Dzierba, PharmD, BCPS, FCCM
Sandra L. Kane-Gill, PharmD, FCCM
Pamela L. Smithburger, MS, PharmD,
BCPS
Robert Witcher, PharmD
Cassandra Baker, PharmD
Kerry E. Francis, PharmD
Akta S. Patel, PharmD
Wanchun Tang, MD, MCCM
Basirat O. Sanuth, PharmD, BCPS
Thomas J. Moran, BCPS, MS, PharmD
John W. Devlin, PharmD, FCCM
Drayton A. Hammond, BCPS, MBA,
PharmD
Hira Shafeeq, BCPS, PharmD
Joseph M. Swanson, PharmD, BCPS
John W. Devlin, PharmD, FCCM
Drayton A. Hammond, BCPS, MBA,
PharmD
Hira Shafeeq, BCPS, PharmD
Joseph M. Swanson, PharmD, BCPS
John Kinsella, MD
Phani C. Kantamneni, MD
Aanchal Kapoor, MD
Christa A. Lenzi, PharmD
Huan Mark Nguyen PharmD, BCPS
Christopher K. Finch, BCPS, PharmD,
FCCM
Ana Negrete, PharmD
Caitlin M. Schaapveld-Davis BCPS,
PharmD
Megan A. Van Berkel, BCPS, PharmD
Jennifer L. Hewlett, PharmD
Volume 15 Issue 4
Abstract
Number
December 2015
Title
Transition from Intravenous to Subcutaneous Insulin
in Critically Ill Adult Patients
268
275
277
Hypoglycemic event rates with two different insulin
protocols in adult intensive care unit patients
Improved glycemic control with collaborative
targeted interventions in a medical ICU
Impact of Injectable Phosphate National Shortage
on Mechanical Ventilation
281
282
290
293
299
304
312
316
317
320
325
338
351
352
358
366
Significance of lactic acidosis and glucose levels in
diabetic ketoacidosis
Comparison of 70/30 biphasic insulin versus insulin
detemir during continuous enteral nutrition
The impact of the cumulative caloric deficit in
critically ill patients
Intensive Care Unit length of stay is associated with
insomnia in critical illness survivors
Precipitating factors associated with Delirium: A
Case-Control study in a UK Intensive Care Unit
Effect of Race on ICU Mortality: A Multi-Center
Retrospective Cohort Study
Cancer patients requiring multiple admissions to the
ICU: Incidence, risk factors, and outcomes
Predictors of ICU admission in cancer patients: A 5year registry-based case-control study
Local culture is a critical factor in adoption of
evidenced based medicine
Barriers and facilitators of high-quality RCTs in
pediatric critical care: A survey of trialists
Long-Stay Patients in Pediatric Intensive Care Units
in Riyadh: A Cross-Sectional Descriptive Study
Likelihood of Rapid Response Patients having
Palliative Care Triggers
The Disconnect Between Patients’ Values and
Preferences for End of Life Care
ICU Patients Receiving Prolonged Life Sustaining
Treatments
Ethical Issues in Critical Care Medicine: Uncovering
the Common and Uncommon Issues
CPP Authors
Meagan Doolin, PharmD
Andrew C. Fritschle Hilliard, PharmD,
BCPS
Serena Ann Harris, PharmD, BCPS
Todd A. Walroth, BCPS, PharmD
Jessica A. Whitten, BCPS
Jeffrey J. Fong, BCPS, PharmD
Katie Nault, MBA, PharmD
Rebeca L. Halfon, PharmD
Michael W. Sirimaturos, PharmD, BCNSP
Abigail D. Antigua, PharmD
Jessica M. Cope, PharmD
Aimee J. Gowler, BCPS, PharmD
Stephen J. Lemon Jr, PharmD
Stacy Alan Voils, BCPS, MS, PharmD
Stephanie Worrall, PharmD
James A. Curtis, BCPS, PharmD
Hal E. Richards, PharmD
Tiffany White, BCPS, PharmD
Katri Abraham, BCPS, PharmD
Ali Paplaskas, PharmD
Krista A. Wahby, PharmD
Raymond J. Yost, PharmD
John Kinsella, MD
Ruth Wan
Nandan Chirumamilla, Research Fellow
Lama Nazer, BCPS, PharmD
Lama Nazer, BCPS, PharmD
Omar Badawi, PharmD, BCPS, FCCM
Erkan Hassan, PharmD, FCCM
Mark Duffett, MSc, RPh
Dr. Mohamad-Hani Temsah, MD
James Gasperino, MD
Tasnim Sinuff, MD
Mary H. Peterson, DNP, MSN, RN, NEABC
Prasad E. Abraham, PharmD, BCPS,
FCCM
Marina Rabinovich, BCPS, PharmD
Volume 15 Issue 4
Abstract
Number
December 2015
Title
378
A Description of Patients in Anhepatic Phase Post
Primary Graft Non-function
Cost-Effectiveness of H2RAs versus PPIs for Stress
Ulcer Prophylaxis in Critically Ill Patients
Organ support, readmission and aetiological factors
in the management of critically ill cirrhotics
Decreased airway complications with glycopyrrolate
prophylaxis for endoscopy: A prospective trial
Timing and utility of Child-Pugh score in patients
with liver cirrhosis referred to ICU
Risk factors for inappropriate stress ulcer
prophylaxis in medical and surgical intensive care
units
The effectiveness of intravenous vitamin K in
cirrhotic patients with coagulopathy in the ICU
379
Discontinuing PPI stress ulcer prophylaxis in the
medical ICU when enteral feeds reach 30 ml/hr
369
370
373
375
376
377
385
390
Comparison of optical density ranges of IgG specific
ELISA utilizing confirmatory results of SRA
Does Early PCC Administration Influence Outcomes
for Warfarin-Associated Intracranial Hemorrhage
Effect of ECMO Use on the Incidence of Severe
Thrombocytopenia during Severe ARDS
394
399
Activated prothrombin complex concentrate or
plasma for reversal of warfarin-associated
coagulopathy
Off-label use of 4-factor prothrombin complex
concentrate for direct oral anticoagulant reversal
401
408
409
411
Comparing three eras of hepatic coagulopathy
normalization using coagulation factor concentrates
Effectiveness and Safety of Four-Factor Prothrombin
Complex Concentrate in Cirrhotic Patients
Efficacy and Safety of 4-PCC for Coagulopathy
Reversal Stratified by FDA Approval Status
CPP Authors
Vikram Dhawan, MD
Drayton A. Hammond, BCPS, MBA,
PharmD
John Kinsella, MD
Jordan E. Anderson, BCPS, PharmD
Abdallah R. Dalabih, MBA, MD
John Kinsella, MD
Phillip Mohorn, BCPS, PharmD
Sandra L. Kane-Gill, PharmD, FCCM
Adam MacLasco, PharmD
Ryan Rivosecchi, PharmD
Nathan Cope, PharmD
Nita F. Johnston, PharmD
Jessica Brown Millen, PharmD
Kevin T. Ferguson, BCPS, PharmD
Maresa D. Glass, BCPS, PharmD
Mitchell J. Daley, PharmD, BCPS
Brady Helmink
Manasa Murthy, PharmD
Abdullah Alhammad, BCPS, PharmD
John W. Devlin, PharmD, FCCM
Amy L. Dzierba, PharmD, BCPS, FCCM
Justin Muir, PharmD
Russel J. Roberts, PharmD
Leslie A. Hamilton, PharmD, BCPS
Anthony Shaun Rowe, BCPS, PharmD
Sandra L. Kane-Gill, PharmD, FCCM
Ryan Rivosecchi, PharmD
Pamela L. Smithburger, MS, PharmD,
BCPS
Cory Weaver, PharmD
Cassie A. Barton, PharmD
Jesse B. Bierman, PharmD
Nathan Dominic Mah, PharmD
Diana Esaian, BCPS, PharmD
Audrey Johnson, PharmD
Caitlin M. Aberle, BCPS, PharmD
John Papadopoulos, BS, PharmD, FCCM
Mitchell J. Daley, PharmD, BCPS
Brady Helmink
Manasa Murthy, PharmD
Volume 15 Issue 4
Abstract
Number
423
424
425
426
433
438
December 2015
Title
Validation and Outcomes of Rapid Molecular
Diagnostic Technology in Culture-Positive Sterile
Fluids
Attributable Risk and Time Course of Colistin
Associated Acute Kidney Injury: Focus on Early
Events
Effect of seizure prophylaxis in LaCrosse
encephalitis
Ampicillin/Sulbactam versus Alternative BetaLactams for Severe Acinetobacter baumannii
Infections
Resistance patterns of uropathogens in patients with
urinary tract infections presenting to the ED
Evaluation of Clinical Trials Including Geriatrics in
the Treatment of HAP
Pathogen and risk factor variation for ventilatorassociated pneumonia in critically ill populations
439
440
447
450
451
452
456
457
459
464
466
Risk Factors for Developing an Early Space
Pulmonary Isolate in Critically Ill Trauma Patients
Incidence of AKI with concomitant vancomycin and
beta-lactams in critically ill patients
Empiric antibiotics for gram-negative bloodstream
infections in ß-lactam allergic ICU patients
The effect of vancomycin and linezolid on the
treatment and outcomes of presumed MRSA
pneumonia
Comparison of High Dose Versus Standard Dose
Oseltamivir in Critically Ill Patients with Influenza
Antimicrobial Treatment and Mortality Risk for
Carbapenem-Resistant Klebsiella pneumoniae
pneumonia
Association between pre-operative cefazolin dose
and surgical site infection in obese patients
Evaluation of a Standardized Antibiotic
Desensitization Protocol
Impact of higher target vancomycin trough levels on
incidence of vancomycin-induced AKI
Aneurysmal Subarachnoid Hemorrhage Patients
with elevated 20-HETE have higher Lindegaard
ratios
CPP Authors
Janelle J Juul, PharmD
William J. Peppard, BCPS, PharmD
Todd A. Miano, PharmD, MSCE
Franklin Huggins, PharmD, BCPS
Kirsten V. Busey, PharmD
Jason Ferreira, PharmD, BCPS
Sarah Albers, PharmD
Elizabeth M. VanWert, PharmD
Marilyn N. Bulloch, PharmD, BCPS
Chris A. Droege, PharmD
Neil E. Ernst, PharmD
Kristen E. Hillebrand, PharmD
Shaun P. Keegan, BCPS, PharmD
Desiree Kosmisky, PharmD
Eric W. Mueller, PharmD, FCCP, FCCM
Aimee Christine LeClaire, PharmD, BCPS,
FCCM
Stephen J. Lemon Jr, PharmD
Stacy Alan Voils, BCPS, MS, PharmD
Drayton A. Hammond, BCPS, MBA,
PharmD
Melanie N. Smith, PharmD
Alley J. Killian, PharmD, BCPS
Nicholas Peters, PharmD, BCPS
Justin Kinney, PharmD
Alexander H. Flannery BCPS, PharmD
Melissa Thompson Bastin, PharmD, BCPS
Stephanie Bass, BCPS, PharmD
Seth R. Bauer, BCPS, PharmD, FCCM
Simon W. Lam, PharmD, BCPS, FCCM
Sarah Welch, PharmD
William J. Peppard, BCPS, PharmD
Kelsey Aker
Keith M. Olsen, PharmD, FCCM
Marilyn N. Bulloch, PharmD, BCPS
Stephen T. Eure, RPh
Samuel M. Poloyac, PharmD, PhD, FCCM
Volume 15 Issue 4
Abstract
Number
468
474
477
478
482
483
484
485
487
490
491
492
493
497
498
503
508
516
531
536
541
December 2015
Title
Delirium risk in surgical intensive care patients on
chronic treatment with gabapentin or pregabalin
Assessment of 23-Valent Pneumococcal Vaccine
Response in Critically-ill Neurosurgical Patients
Association of Osmolality, Brain Volume, and
Clinical Neurologic Changes in Hepatic
Encephalopathy
Efficacy and Safety of Clevidipine and Nicardipine in
Post-Neurosurgery Patients
Pharmacists’ Impact on Door-to-Needle Time in
Acute Ischemic Stroke
Prothrombin complex concentrate vs. fresh-frozen
plasma in warfarin-associated ICH
Next generation gene expression analysis shows
decreased expression of transporters following TBI
Sleep in the ICU: An Analysis of Sleep Quality and
Quantity in Mechanically Ventilated Patients
IRL-1620 provides neuroprotection and enhances
angiogenesis in diabetic rats with cerebral ischemia
CSF concentration of Vancomycin compared to
serum during continuous infusion in adult patients
Glibenclamide reduces diffuse cerebral edema in a
combined model of traumatic brain injury and shock
Fever Control in Brain Injury with a Rapid Infusion of
4°C Normal Saline: Efficacy and Safety Trial
Evaluation of prothrombin complex reversal
strategies in patients with warfarin-associated ICH
Multi-faceted approach to reducing delirium in a
medical intensive care unit
Lacosamide for Treatment of Status Epilepticus: A
Safe and Effective Option
Systolic Dysfunction Following Moderate-Severe
Traumatic Brain Injury
Comparison of lurasidone versus quetiapine for the
treatment of delirium in critically ill patients
Paroxysmal sympathetic hyperactivity after acquired
brain injury in critically ill children
Clevidipine Versus Nicardipine for Acute Blood
Pressure Lowering in the Neuroscience ICU
Initial Experience with 23% hypertonic saline for
cerebral edema in Pediatric Intensive Care
Risk of resistant microorganisms with prolonged
antibiotic prophylaxis for intracranial devices
CPP Authors
Lisa M. Harinstein, BCPS, PharmD
Douglas N. Fish, BCPS, PharmD, FCCM
Tyree H. Kiser, PharmD, BCPS, FCCM
Robert MacLaren, MPH, PharmD, FCCM
Scott W. Mueller, BCPS, PharmD
Bryan D. Lizza, BCPS, PharmD
Ola Elnadoury, PharmD
Joseph Samide, PharmD
Joe Bodkin, PharmD
Elisabeth Donahey, BCPS, PharmD
Megan A. Rech, BCPS, PharmD
Mindee Sue Hite, PharmD
Kevin M. Silinskie, PharmD
Solomon M. Adams, PharmD
Philip E. Empey, PharmD, PhD, BCPS
Raymonde Jean, MD
Anil Gulati, MD, PhD
Jessica Louie, PharmD
Samuel M. Poloyac, PharmD, PhD, FCCM
Matthew J. Korobey, BCPS, PharmD
Sperry Kotsianas, PharmD
Jennifer Cortes, BCPS
Gregory M. Norris, MD
Dennis Parker Jr, PharmD
Vijay Krishnamoorthy, MD
Jessica Elefritz, PharmD
Jennifer L. Hewlett, PharmD
Gretchen M. Brophy, BCPS, PharmD,
FCCM
Lisa M. Kurczewski, PharmD, BCPS
Lois F. Parker, BS, RPh, FASHP
Stephanie Chauv, PharmD
Gabriel V. Fontaine BCPS, PharmD
Quang P. Hoang, BCPS, PharmD
Courtney B. McKinney, BCPS, PharmD
Volume 15 Issue 4
Abstract
Number
545
546
548
549
552
560
566
570
572
575
576
577
578
579
December 2015
Title
Effects of vitamin D deficiency in aneurysmal
subarachnoid hemorrhage.
Retrospective Comparison of Alpha-2 Agonists for
Alcohol Withdrawal in the MICU
Evaluation of Outcomes Associated with
Vasopressin Use in Aneurysmal Subarachnoid
Hemorrhage
Does the number of comorbidities before ICU
admission influence quality of life after ICU?
Provider and Family Perceptions of Family
Involvement in Delirium Prevention in an ICU
Carer Strain in Caregivers of ICU survivors
Is there are relationship between perceived self
efficacy and quality of life in ICU survivors?
Precipitating causes associated with diabetic
ketoacidosis in adult patients
Characterization of Patient Referrals to a PostIntensive Care Syndrome (PICS) Recovery Center
Drug history as a measure of comorbidity and
predictor of long term outcome following ICU
admission
Comparison of hemodynamic ADEs associated with
dexmedetomidine and propofol in ICU patients
Impact of Intravenous Acetaminophen in
Cardiothoracic Surgery Patients
Population Pharmacokinetics (PK) of Vancomycin in
Children on Extra-Corporeal Life Support (ECLS)
Intravenous heparin calculation errors pre- and postimplementation of the Heparin NOCLOT Wizard
International Survey of Pharmacologic VTE
Prophylaxis Practice in Critically Ill Obese Patients
580
581
582
583
584
585
586
Clinical impact of hyperchloremia secondary to
hypertonic sodium chloride administration
Current Practices and Safety of Medication Use
During Rapid Sequence Intubation (RSI)
Population Pharmacokinetics (PK) of Vancomycin
(VAN) in Neonates on Extra-Corporeal Life Support
Thrombotic Complications after Prothrombin
Complex Concentrate (Kcentra) Administration
Evaluation of discontinuation of quetiapine and
haloperidol prescribed for acute ICU delirium
Ketamine infusion as adjunct sedation in
mechanically ventilated critically ill patients
CPP Authors
Yarelis Alvarado, BCPS, PharmD
Bryan D. Lizza, BCPS, PharmD
Lisa L. Forsyth, PharmD
Allycia Natavio, PharmD
Kyle Schmidt, PharmD
John Kinsella, MD
Sandra L. Kane-Gill, PharmD, FCCM
Pamela L. Smithburger, MS, PharmD,
BCPS
John Kinsella, MD
John Kinsella, MD
Katie Langley
Sarah Bloom, ACNP, BSN, CCRN, MSN
Joanna L. Stollings, PharmD, BCPS
John Kinsella, MD
Mallory A. Fiorenza, PharmD, BCPS
Amy West, PharmD
Seth R. Bauer, BCPS, PharmD, FCCM
Matthew R. Wanek, BCPS, PharmD
Jeffrey J. Cies, PharmD, MPH, BCPS
Sarah Providence, BCPS, PharmD
Abigail D. Antigua, PharmD
Jessica M. Cope, PharmD
Aimee J. Gowler, BCPS, PharmD
Stephen J. Lemon Jr, PharmD
Stacy Alan Voils, BCPS, MS, PharmD
Chris A. Droege, PharmD
Neil E. Ernst, PharmD
Shaun P. Keegan, BCPS, PharmD
Eric W. Mueller, PharmD, FCCP, FCCM
Christine Marie Groth, BCPS, PharmD
Jeffrey J. Cies, PharmD, MPH, BCPS
Emily J. Owen, PharmD
Rachel C. Stratman Wolfe PharmD
Mallory A. Fiorenza, PharmD, BCPS
Jonathan Girnys, PharmD
Lara Groetzinger, BCPS, PharmD
Ryan Rivosecchi, PharmD
Volume 15 Issue 4
Abstract
Number
December 2015
Title
A national evaluation of ICU delirium identification,
prevention and treatment practices
587
588
Anti-Factor Xa Testing for Quantifying Anticoagulant
Effect due to Oral Direct Xa Inhibitors
598
Effectiveness of an Algorithm for Glucose
Management in Critical Care
Vancomycin Dosing and Pharmacokinetics in PostOperative Pediatric Cardiothoracic Surgery Patients
Sedation and neuromuscular blockade in adults
receiving extracorporeal membrane oxygenation
Ketamine use for sedation management in patients
receiving extracorporeal membrane oxygenation
The incidence of hypotension with continuous
infusion atracurium compared to cisatracurium
The Pharmacokinetics of Dexmedetomidine in
Infants and Children following Isolated Orthotopic
Liver
The Persistence of ICU Delirium after Cessation of
Sedatives and Analgesics
599
Evaluation of thromboelastography (TEG) for VTE
prophylaxis in liver failure patients
600
Association Between Compliance to the Yale
Alcohol Withdrawal Protocol and Outcomes
591
592
593
594
595
597
601
602
603
605
606
607
608
Propensity matched analysis comparing hypotension
between etomidate and ketamine in septic patients
Do antipsychotics improve ICU outcomes in patients
with delirium ?
High- versus Low-dose Recombinant Activated
Factor VII Use in Cardiac Surgery Patients
Association of insulin dose, diabetes, and dialysis
with hypoglycemia in treatment of hyperkalemia
Evaluation of antithrombin supplementation on
heparin anticoagulation in pediatric ECMO patients
Rivaroxaban vs. Standard of Care Post Ultrasound
Accelerated Thrombolysis for Pulmonary Embolism
Evaluation of a low-dose heparin nomogram for
cardiac surgery patients with high bleeding risk
CPP Authors
John W. Devlin, PharmD, FCCM
Amy L. Dzierba, PharmD, BCPS, FCCM
Sandra L. Kane-Gill, PharmD, FCCM
Pamela L. Smithburger, MS, PharmD,
BCPS
Joshua T. Swan, BCPS, PharmD
Jake Beyer, BS, PharmD
Tyree H. Kiser, PharmD, BCPS, FCCM
Toby C. Trujillo, BCPS, PharmD, FCCP
Lina Huang, BCPS, PharmD
Peter N. Johnson, BCPS, PharmD
Jeremy DeGrado, PharmD
Amy L. Dzierba, PharmD, BCPS, FCCM
Justin Muir, PharmD
Anthony T. Gerlach, BCPS, PharmD,
FCCM
Felice Su, MD
Timothy D. Girard, MD
Michael Kenes, BCPS, PharmD
Joanna L. Stollings, PharmD, BCPS
Jeffrey T. Fish, PharmD
Jennifer Garber, PharmD
Chris Viesselmann, PharmD
Maria Cardinale, PharmD BCPS
Claire Y. Chan, BCPS, PharmD
Mojdeh S. Heavner, BCPS, PharmD
Bruce Allan Doepker, BCPS, PharmD
Kari L. Cape, PharmD, BCPS
Lindsay Pell Ryder, BCPS, BCPS
Megan A. Van Berkel, BCPS, PharmD
Juliane Jablonski, CCRN, CNS, DNP, RN
Todd A. Miano, PharmD, MSCE
Joel Feih, PharmD
Markus Kaiser, MD
Heather A LaRue PharmD
Sharon Gordon PharmD
Claudia Lynn Dubois, BCPS, PharmD
Patricia R. Louzon, PharmD, BCPS
Ashleigh Lowery, PharmD
Mehrnaz Pajoumand, BCPS, PharmD
Carla Williams, BCPS, PharmD
Volume 15 Issue 4
Abstract
Number
December 2015
Title
Are we providing adequate analgesia & sedation to
critically ill, mechanically-ventilated patients?
609
610
612
614
615
Impact of improved sedation practices on positive
outcomes in critically ill patients
Vitamin D deficiency in a cardiac surgery intensive
care unit: Standard doses are not enough
Warfarin Reversal in ICH: activated versus
inactivated four factor prothrombin complex
concentrates
Intrapleural fibrinolytic and DNAse therapy for
pleural infection leads to surgical avoidance
Clinical and Pharmacokinetic Evaluation of Oral
Acetaminophen Absorption in Critically Ill Patients
616
617
618
619
620
621
622
623
624
625
626
Use of Intravenous Sildenafil in Pediatric Patients at
an Academic Children’s Hospital
Increased Neonatal Vancomycin Trough Levels and
Incidence of Ototoxicity/Nephrotoxicity in the NICU
Mechanically Ventilated ICU Patients’ Sedative Selfadministration: Impact on Medication Received
Lack of Change in Oxygen Consumption following
Albuterol compared to Levalbuterol in Healthy Adults
An Evaluation of Norepinephrine Dosing Strategies
in Morbidly Obese Patients with Septic Shock
Evaluation of pharmacist vs nurse assessed
confusion assessment method for the intensive care
unit
Impact of Variable Re-Dosing Strategies on INR
after Prothrombin Complex Concentrate (Kcentra)
The impact of early analgesia on outcomes in
mechanically ventilated patients
Weight-based Heparin Nomogram for Critically Ill
Patients with High Bleeding Risk
Drug Desensitization: Outcomes and Risk Factors
for skin reactions in adults
CPP Authors
Lisa Hall Zimmerman, PharmD, BCPS,
FCCM
Lesly Jurado, PharmD
Steven H. Nakajima, PharmD
Joshua D. Steelman, PharmD
Darowan Akajagbor, BCPS, PharmD
William Darko, PharmD
Kayla Kotch, PharmD
Ashleigh Lowery, PharmD
Kasey Greathouse, PharmD, BCPS
Mary Lenefsky, PharmD
Kimberly Elisabeth Levasseur-Franklin,
BCPS, PharmD
Michele Handzel, PharmD
Cara McDaniel, BCPS, PharmD
Chris A. Droege, PharmD
Neil E. Ernst, PharmD
Shaun P. Keegan, BCPS, PharmD
Eric W. Mueller, PharmD, FCCP, FCCM
Megan Welch, PharmD
Kristine Parbuoni, BCPS, PharmD
Elizna Van Zyl
Anita Siu, PharmD, BS
Sarah Maryon Hayes, BS, PharmD
Debra J. Skaar, PharmD, FCCM
Manpreet Virk, MD
Alexander H. Flannery BCPS, PharmD
Komal A. Pandya, PharmD
Paul Wong, PharmD
Jennifer S. Catlin, BCPS, PharmD
Livia Mackley, PharmD
Gabrielle A. Gibson, BCPS, PharmD
Emily J. Owen, PharmD
Rachel C. Stratman Wolfe PharmD
Heath Oetken, PharmD
Keith M. Olsen, PharmD, FCCM
Sai-Ho Jason Chui, BCPS, PharmD
Mehrnaz Pajoumand, BCPS, PharmD
Sharon Wilson, BCPS, PharmD
Taryn Murray, PharmD
Joanna L. Stollings, PharmD, BCPS
Volume 15 Issue 4
Abstract
Number
December 2015
Title
Three versus Four-Factor Prothrombin Complex
Concentrate for Reversal of Warfarin-Induced
Bleeding
628
629
630
631
632
633
634
635
637
642
643
644
645
646
647
648
649
650
The half-life of acetaminophen and its relationship to
mortality after acetaminophen overdose
Major Bleed Risk in Patients on Novel Oral
Anticoagulants with PGP and/or CYP450 3A4
Inhibitors
Tolerability of Subanesthetic Ketamine in the
Surgical Intensive Care Unit
Comparison of Neuromuscular Blockers in Early
Acute Respiratory Distress Syndrome
Do Norepinephrine Starting Rates Effect Outcomes
in Septic Shock?
Characterization Of Pharmacy Interventions In A
Post Intensive Care Unit Recovery Center
Efficacy and Safety of Intraventricular Antibiotics in
Critically Ill Neurosurgical Patients
Impact of Over-Sedation and Inadequate Pain
Control on Duration of Intubation in Oncology
Patients
High vs. low dose sulfamethoxazole/trimethoprim for
the treatment of Stenotrophomonas pneumonia
Evaluation of propofol (Diprivan) monitoring
practices in adult intensive care units
Does dexmedetomidine reduce opioid requirements
in brain injured patients
Safety of Analgesia-based Sedation in the Trauma
Intensive Care Unit (ICU)
Improving Administration of Weight-Based
Vancomycin Loading Doses in the ED Through PreBuilt Orders
Evaluation of delirium monitoring in a medical ICU
Evaluation of the Appropriateness of Initial Antibiotic
Dosing in Severe Sepsis and Septic Shock
Dexmedetomidine (DEX) Prescribing Patterns for
Mechanically Ventilated (MV) Patients
Insufficient use of analgesia and anxiolysis in postintubated patients in the ED
CPP Authors
Prasad E. Abraham, PharmD, BCPS,
FCCM
Tai Elder, PharmD
Serena Ann Harris, PharmD, BCPS
Tara R. Holt, BCPS, PharmD
Wesley D. McMillian, BCPS, PharmD,
FCCM
Laura Hencken, PharmD
Michael A. Peters, BCPS
John Stine, PharmD, BCPS
Caroline J. Girardeau, BCPS, PharmD
Debbie Liang, PharmD
Mona K. Patel, PharmD
Leanne M. Current, BCPS, PharmD
Charles J. Kramer, BCPS, PharmD
Krista A. Wahby, PharmD
Kara Zacholski, PharmD
Sarah Bloom, ACNP, BSN, CCRN, MSN
Joanna L. Stollings, PharmD, BCPS
Colleen Barthol, BCPS, PharmD
Molly Curran
Trisha Patel, BCPS, PharmD
Michelle Horng, BCPS, PharmD
Lisa M. Kurczewski, PharmD, BCPS
Kimberly L. Varney Gill, BCPS, PharmD
Ali Paplaskas, PharmD
Linda A. Park, BCPS, PharmD
Dennis O. Parker Jr, PharmD
Maria L. Pusnik, BCPS, PharmD
Brandon P. Hobbs, PharmD
Xi Liu-DeRyke, PharmD, FCCM
Joseph Hai Trang, PharmD
Colleen Teevan, BCPS, PharmD
Amy L. Dzierba, PharmD, BCPS, FCCM
Justin Muir, PharmD
Phil Grgurich, PharmD, BCPS
Laura M. Bosse, PharmD
Suprat Saely Wilson BCPS, PharmD,
PharmD
Volume 15 Issue 4
Abstract
Number
651
652
653
654
656
657
December 2015
Title
Potential prolonged effects of argatroban in the
critically ill
Prothrombin Complex Concentrate (Kcentra) for
Reversal of Oral Factor Xa Inhibitors
Risk factors associated with elevated vancomycin
trough concentrations in a Medical ICU
Risk Factors for the Development of Hemodynamic
Adverse Effects with Dexmedetomidine
Efficacy of Sequential Nephron Blockade in Pediatric
Cardiac Intensive Care Patients
Continuous Sedation with Midazolam in Obese vs
Non-Obese Critically Ill Patients
Implementation and Perceptions of a Critical Care
Pharmacists’ Mentor-Mentee Program
659
660
661
662
666
672
686
690
694
702
705
708
719
723
Using social media to increase the reach of SCCM’s
Critical Care Congress
Diversity in the Emerging Intensivist Workforce:
Trends in Critical Care Fellows from 2004-2014
Impact of a Clinical Pharmacist Participating in
Multidisciplinary rounds in an ICU Setting
High-Flow Nasal Cannula Flow Titration and Effort of
Breathing in the Pediatric Intensive Care Unit
Derivation of a Bundle to Improve First Attempt
Success at Intubation in the Intensive Care Unit
Predictors of Difficult Intubation When Using Video
Laryngoscopy in the Intensive Care Unit
Thrombotic outcomes with an unfractionated heparin
guideline in extracorporeal membrane oxygenation
Fixed-Dose Cisatracurium in Acute Respiratory
Distress Syndrome: Sedation and Analgesia
Efficacy of High Flow/High Humidity Nasal Cannula
Therapy in Viral Bronchiolitis
Use of a common canister metered dose inhaler
protocol in mechanically ventilated patients
Steroid Dosing Relationship to Duration of
Mechanical Ventilation in Acute COPD
Exacerbations
High Dose Oseltamivir and ARDS Adjunct Therapy
in Severe Influenza: A Comparison of Two
Outbreaks
Pediatric Cystic Fibrosis (CF) Patients Requiring
Endotracheal Intubation: National Mortality Trends
CPP Authors
Earnest Alexander Jr, PharmD, FCCM
Uyen Diep
Melissa M. Giarratano, PharmD
Maresa D. Glass, BCPS, PharmD
Emily J. Owen, PharmD
Rachel C. Stratman Wolfe PharmD
Steven E. Pass, PharmD, FCCM
Alexander H. Flannery BCPS, PharmD
Jeremy D. Flynn, PharmD, FCCP, FCCM
Ahmed A. Mahmoud, PharmD
Ronald A. Bronicki, MD, FCCM
Erin E. Mancl, PharmD, BCPS
Megan A. Rech, BCPS, PharmD
Susan E. Hamblin, PharmD, BCPS
Drayton A. Hammond, BCPS, MBA,
PharmD
Serena Ann Harris, PharmD, BCPS
Brian J. Kopp, BCPS, PharmD, FCCM
Elizabeth H. Mack, MD, MS
Todd A. Miano, PharmD, MSCE
Thomas Bushell, PharmD
Nam Cho BCPS, PharmD
Asavari Kamerkar, MD
John W. Bloom, MD
John W. Bloom, MD
Amy L. Dzierba, PharmD, BCPS, FCCM
Justin Muir, PharmD
Amanda M. Ball, BCPS, PharmD
Rebecca Bookstaver, BSN, PharmD
Catherine A. Pierce, PharmD, FCCM
Patricia A. Abboud, MD
Jennifer Bushwitz, PharmD
Mollie Gowan, PharmD
Katherine Kielts, PharmD
Jennifer McCann, PharmD, BCPS
Jeffrey P. Gonzales, BCPS, PharmD,
FCCM
Steven D. Strausbaugh, MD, FCCP, CPI
Volume 15 Issue 4
Abstract
Number
747
750
751
758
768
773
784
787
797
799
802
805
810
818
822
826
834
840
841
847
850
858
862
December 2015
Title
High vs. low dose corticosteroids in COPD
exacerbations requiring mechanical ventilation
Evaluating Methylprednisolone Doses in Intensive
Care Unit Patients for Acute COPD Exacerbation
Healthcare-associated pneumonia treatment
characterization in medical intensive care unit
patients
Trend and outcomes of video laryngoscope use
across pediatric ICUs
Effect of an Audit and Feedback Process on Pain,
Agitation, and Delirium Documentation in 15 ICUs
Impact of a team initiative to reduce unplanned
extubations in patients with difficult airways
Interprofessional Collaboration on Delirium
Management in a Pediatric Intensive Care Unit
Multi-center validation of an ICU real-time prediction
of mortality (RPM) model
Experience with Propofol for Procedural Sedation in
Infants under 6 months of Age.
Reduction in Point-of-Care Blood Glucose
Measurements in the Medical Intensive Care Unit
Inappropriate Continuation of Acid Suppression
Therapy in Intensive Care Unit Patients
Increasing event reporting by residents in a pediatric
intensive care unit
Evaluation and Potential Impact of Critical Care
Pharmacists’ Interventions in Singapore
Incidence of Atypical Antipsychotic Prescription at
Time of ICU and Hospital Discharge
Using Physician Champions To Coordinate
Spontaneous Awakening And Breathing Trials
Effect of a “Re-invigorated” RRT on In-hospital
Cardiopulmonary Arrest Rates and Mortality.
Discrepancies in Measuring Bladder Volumes with
Bedside Ultrasound and Bladder Scanning in the
ICU
Discharge Prescribing of Enteral Opiates After Use
as a Weaning Strategy from Intravenous Opiates
Experience with Implementation of Pain Agitation
and Delirium Guidelines in MICU
Prospective Evaluation of an Automated Severity
Score’s ability to differentiate ICU patients
High versus Standard Dose Dexmedetomidine for
Sedation in Critically Ill Patients: The HI-DEX Study
Structure and function of teams in the PICU: A social
network analysis
Economic Impact of Clinical Pharmacy Services at
an Academic Teaching Hospital
CPP Authors
Jennifer Cortes, BCPS
Richard Lawrence McKnight, PharmD
Jeffrey M. Quedado, PharmD
Jeffrey P. Gonzales, BCPS, PharmD,
FCCM
Eleanor Gradidge, MD
Pradip P. Kamat, MBA, MD
Stacey L. Folse, BCPS, MPH, PharmD
Pradip P. Kamat, MBA, MD
Allison Lardieri, PharmD
Omar Badawi, PharmD, BCPS, FCCM
Erkan Hassan, PharmD, FCCM
Pradip P. Kamat, MBA, MD
Seth R. Bauer, BCPS, PharmD, FCCM
Kaitlin Pruskowski, PharmD
Elizabeth H. Mack, MD, MS
Simeon Tang, PharmD
Matthew J. Korobey, BCPS, PharmD
Frantz Hastrup, MD
Samad Rasul, MD, FACP
Warren Isakow, MD
Marilyn Schallom, CCRN, PhD, FCCM
Dan Gilstrap, MD
Bridgette L. Kram, PharmD, BCPS
Stacey L. Folse, BCPS, MPH, PharmD
Omar Badawi, PharmD, BCPS, FCCM
Erkan Hassan, PharmD, FCCM
Rebecca L. Anderson, BCPS, PharmD
Mark Duffett, MSc, RPh
Martha A. Naber, PharmD
Edward G. Timm, PharmD
Volume 15 Issue 4
Abstract
Number
864
872
876
891
892
893
896
902
903
904
905
906
911
912
919
920
924
925
927
932
934
December 2015
Title
Reduction in S. aureus nasal screening in MICU
reduces lab costs without increase in Lab ID events
Experience and Satisfaction with Early Mobility in
Mechanically Ventilated Cancer Patients
Impact of Expanding Emergency Medicine
Pharmacy Services in a Community Hospital
Transport Risk Assessment in Pediatrics Score
Predicts Clinical Course of Critically Ill Children
Staff and family satisfaction with implementation of a
safe pediatric sedation checklist
Evaluation of azithromycin administration and QTcinterval prolongation in the critically ill
The creation of the first ICU Patient and Family
Advisory Council in the UK
Standardization of anticoagulation management in
extracorporeal membrane oxygenation
Implementation of clinical decision support tool for
the management of HIT in the ICU
Improving Hand Hygiene Compliance In Hospital
Care
Characterization of Warfarin Major Bleeding Events
in Real-World Clinical Practice
Impact of pharmacists on transition of care from
intensive care to progressive care units
Evaluation of inappropriate unable-to-assess CAMICU documentations of critically ill patients
Safety of the Peripheral Administration of
Vasopressor Agents
The Impact of Mobility and Sedation Protocols on
Delirium in Mechanically Ventilated Patients
Utility of an Osmolar Gap and Other Laboratory
Values in the Diagnosis of Toxic Alcohol Ingestion
Medication Utilization and Outcomes with
Implementation of the Critical-Care Pain Observation
Tool
Evaluation of risk factors for high vancomycin
troughs in pediatric patients
Sedation and analgesia utilization following rapid
sequence intubation in the emergency department
Impact of reflex urine studies on antimicrobial use
and healthcare costs in the intensive care unit
Evaluation of Diabetic Ketoacidosis/Hyperosmolar
Hyperglycemic State Protocol at an Academic
Center
CPP Authors
Seth R. Bauer, BCPS, PharmD, FCCM
Louis P. Voigt, MD
Darlene Chaykosky, PharmD, BCPS
Rosa L. Haddock, MD
Gilberto Puig, MD
Elizabeth H. Mack, MD, MS
Anna Fiorvento
Linda A. Park, BCPS, PharmD
Maria L. Pusnik, BCPS, PharmD
John Kinsella, MD
Chris Viesselmann, PharmD
Marina Rabinovich, BCPS, PharmD
Venkatesh Aiyagari, MD
Maureen A. Smythe, PharmD, BCPS
Patricia R. Louzon, PharmD, BCPS
Paul M. Szumita, BCPS, PharmD
Kimberly Terry, BCPS, PharmD
Diana Esaian, BCPS, PharmD
Tyler Lewis, PharmD
Cristian Merchan, PharmD
John Papadopoulos, BS, PharmD, FCCM
James A. Curtis, BCPS, PharmD
Neil Roe, PharmD
Megan A. Van Berkel, BCPS, PharmD
Alexis Luckey, PharmD
Jodi L. Taylor, BCPS, PharmD
Bethany Ann Wattles, PharmD
Cindy Zoeller, PharmD, MBA
Michele Handzel, PharmD
Cara McDaniel, BCPS, PharmD
Marian Gaviola, PharmD
Wesley D. McMillian, BCPS, PharmD,
FCCM
Marina Rabinovich, BCPS, PharmD
Volume 15 Issue 4
Abstract
Number
941
949
953
955
963
968
973
975
976
995
998
1014
December 2015
Title
Ventilator Weaning Protocol Reduces Duration of
Ventilation in a Pediatric ICU
Evaluation of neuroleptic utilization in the intensive
care unit during transitions of care
Developing a standardized OR to ICU handoff
process
Evaluation of Phenytoin Monitoring Practices in
Adult Critically ill Patients
Post-operative Acute Kidney Injury among Patients
Admitted from the Emergency Room for Major
Surgery
Plasma resistin levels are associated with acute
kidney injury in critically ill trauma patients
Are There Differences in the Risk Factors for AKI in
Young Adults as Compared to Older Adults?
A Unique Application of the GRADE Criteria: DrugCombination Associated AKI
Characteristics & Outcomes of severe hyponatremia
(Na=125 meq/L) in the MICU: A retrospective study
The Impact of Endocrine Supplementation on
Adverse Events in Septic Shock
Type 2/Th2 Inflammatory Responses Protect
Against the Mortality of Staphylococcus aureus
Infection
ABO Blood Type A and Increased Severity of Sepsis
Association between intravenous fluid chloride
content and acute kidney injury in adults with sepsis
1027
1035
1043
1048
1051
1053
1057
Impact of hydrocortisone continuous infusion versus
bolus dose on glycemic control
Shock Index as a Predictor of ICU Transfer in
Patients Admitted to the Medical Ward with Sepsis
Vitamin D Supplementation and Mortality in Patients
with Severe Sepsis and Septic Shock
Efficacy of non-weight based vasopressor dosing in
critically ill patients with severe sepsis
Impact of Pharmacist Intervention on Timing of
Appropriate Antimicrobial Therapy in Septic Shock
Impact of Educational Interventions and Simulation
Training on Mortality in a Busy Urban Hospital
CPP Authors
Sameer Kamath, MD
Jason Ferreira, PharmD, BCPS
Juliane Jablonski, CCRN, CNS, DNP, RN
Nadia H. Ismail, BS, MS
Joshua T. Swan, BCPS, PharmD
Daniel N. Holena, MD
Sandra L. Kane-Gill, PharmD, FCCM
Joseph F. Dasta, MS, RPh, MCCM, MSc
Sandra L. Kane-Gill, PharmD, FCCM
Ryan Rivosecchi, PharmD
Phani C. Kantamneni, MD
Brittany Dawn Bissell, PharmD
Michael J. Erdman, PharmD, BCPS
Jason Ferreira, PharmD, BCPS
Philip A. Verhoef, MD, PhD
Megan A. Rech, BCPS, PharmD
Bruce Allan Doepker, BCPS, PharmD
Kari L. Cape, PharmD, BCPS
Claire V. Murphy, PharmD
Megan Perry, PharmD
Lindsay Pell Ryder, BCPS, BCPS
Christy C. Forehand, BCPS, PharmD
April Miller Quidley, PharmD, BCPS, FCCM
Laura Zane, PharmD
Isaac Noble Biney, MD
Megan A. Rech, BCPS, PharmD
Bryan Allen, PharmD
Alexander H. Flannery BCPS, PharmD
Jeremy D. Flynn, PharmD, FCCP, FCCM
Raymonde Jean, MD
Volume 15 Issue 4
Abstract
Number
December 2015
Title
Impact of prior antihypertensive therapy on
outcomes for patients with circulatory shock
1059
1061
Impact of order set utilization for the treatment of
patients with severe sepsis and septic shock
1077
Fluid Resuscitation in Septic Shock Patients
Perceived At Risk for Volume Overload
Patients metabolomic profile in intensive care unit.
ECMO in H1N1 Pregnant and Postpartum Women
with ARDS: A Systematic Review and Metaanalysis.
Sepsis without Walls: A Quality Improvement Project
The Influence of Sepsis on Sleep Architecture in the
Intensive Care Unit
Predictors of Outcomes with Endocrine Support in
Septic Shock
1079
Evaluation of a Severe Sepsis Order Set in the
Surgical Intensive Care Unit
1062
1063
1067
1069
1075
1084
Evaluation of Code Sepsis at a Urban Community
Teaching Hospital
Enoxaparin Versus Anti-Xa Adjusted Dalteparin for
Venous Thromboembolism Prophylaxis in Trauma
1108
1109
1113
1116
1119
1126
1127
1131
1135
Empiric antibiotic selection for ventilator associated
pneumonia in traumatically-injured patients
Hypertonic saline and acute kidney injury in
traumatic brain injury
Dronabinol for Acute Pain Management in Burn
Patients that Use Marijuana
Predictors of Contrast Induced Nephropathy in
Trauma Patients
Antibiotic Evaluation Following Penetrating
Abdominal Injury With and Without Orthopedic Injury
Adjunct Ketamine Infusions Provide Improved Acute
Traumatic and Post-Surgical Pain Management
Comparison of tranexamic acid and aminocaproic
acid in blood loss reduction in orthopedic surgeries
Impact of a nursing-driven sedation protocol on
mechanical ventilation in the surgical ICU
CPP Authors
Seth R. Bauer, BCPS, PharmD, FCCM
Mitchell J. Daley, PharmD, BCPS
Ishaq Lat, PharmD, FCCM
Robert MacLaren, MPH, PharmD, FCCM
Russel J. Roberts, PharmD
Sarah S. Sokol, PharmD
Lucretia C. Davis, PharmD
Petra Grami, BSN, CCRN, NE-BC
Chiamaka Ike, BCPS, PharmD
Christa A. Schorr, RN, MSN, FCCM
Dr. Patrick Biston, MD
Antonio Saad, MD
James Gasperino, MD
Raymonde Jean, MD
Brittany Dawn Bissell, PharmD
Michael J. Erdman, PharmD, BCPS
Jason Ferreira, PharmD, BCPS
Andrew S. Jarrell, BCPS, PharmD, PharmD
Rachel M. Kruer, BCPS, PharmD
Alan Rozycki, PharmD
Basirat O. Sanuth, PharmD, BCPS
Chris A. Droege, PharmD
Neil E. Ernst, PharmD
Shaun P. Keegan, BCPS, PharmD
Eric W. Mueller, PharmD, FCCP, FCCM
Megan Welch, PharmD
Melissa A. Reger, BCPS, PharmD, RPh
Susan E. Hamblin, PharmD, BCPS
Kelly Maguigan, PharmD
Charles J. Foster, BCPS, PharmD
Christopher Miller, PharmD
Scott W. Mueller, BCPS, PharmD
John A. Bethea, PharmD
Lauren R. Jones, PharmD
Eric W. Mueller, PharmD, FCCP, FCCM
Madeline Foertsch BCPS, PharmD
Meghann Luc, PharmD
Caitlin F. Mulllins, PharmD
William J. Peppard, BCPS, PharmD
Bryan Allen, PharmD
Justin Kaplan, PharmD
Claire V. Murphy, PharmD
Volume 15 Issue 4
Abstract
Number
1140
1142
1145
1147
1149
1152
1158
1163
1164
1169
1172
1173
1179
1180
1182
1186
1188
1190
1199
1204
December 2015
Title
Use of a Computerized Heparin Protocol Improves
Patient Safety in the Surgical Intensive Care Unit
Do Intracranial Pressure Monitors Improve Survival
in Pediatric Traumatic Brain Injury Patients?
Comparison of vancomycin dosing in
hypermetabolic vs non-hypermetabolic patients with
thermal injury
Evaluation of tranexamic acid as part of a massive
transfusion protocol at a Level 1 Trauma Center
The Effect of Antipsychotic Use Post Traumatic
Brain Injury on Duration of Post Traumatic Amnesia
Serum sodium (sNa) response to hypertonic saline
(HTS) in traumatic brain injury (TBI)
Methicillin-resistant Staphylococcus aureus
pneumonia in critically ill trauma patients
Evaluation of Dose to INR response of PCC3 and
PCC4 to INR Reduction in Emergent Warfarin
Reversal
Assessment of a Tranexamic Acid Protocol for
Orthopedic Trauma Surgery
Urine sodium excretion and serum sodium changes
with hypertonic saline for traumatic brain injury
Prophylactic Enoxaparin Dosing Strategies and
Incidence of Venous Thromboembolism in Burn
Patients
Increased Red Cell Distribution Width is Associated
with Mortality Following Burn Injury
Early hypercoagulability in trauma ICU patients
detected by calibrated automated thrombogram
Respiratory depression in the intoxicated trauma
patient: Are opioids to blame?
Trauma patients admitted taking warfarin or
dabigatran - A comparison of management and
outcomes
Reduction in Red Blood Cell Utilization Associated
with a Blood Conservation Initiative in a SICU
Outcomes of trauma patients not receiving
antibiotics for polymicrobial growth of BAL
Early VENous Thromboembolism prophylaxis in
blunt trauma: The EVENT Study
Ceftolozane-tazobactam pharmacokinetics in a
patient on continuous veno-venous hemofiltration
Activated PCC (FEIBA) for reversal of rivaroxabaninduced life-threatening bleeding - a case series
CPP Authors
Kelli Rumbaugh, PharmD
Mathew Mathew Edavettal MD, PhD
Brittainy Allen, PharmD
Megan A. Rech, BCPS, PharmD
Melissa A. Reger, BCPS, PharmD, RPh
Ann W. Vu, BCPS, PharmD
Kirstin J. Kooda, BCPS, PharmD
Scott A. Chapman, PharmD
Charles Andrew Adams Jr, MD, FCCM
Kristen Bunnell, PharmD
Scott A. Chapman, PharmD
Meagan Doolin, PharmD
Serena Ann Harris, PharmD, BCPS
Todd A. Walroth, BCPS, PharmD
Scott A. Chapman, PharmD
David R. Foster, BS, PharmD
Andrew C. Fritschle Hilliard, PharmD,
BCPS
Todd A. Walroth, BCPS, PharmD
Jessica A. Whitten, BCPS
Nam K. Tran, PhD
Stephen J. Lemon Jr, PharmD
Stacy Alan Voils, BCPS, MS, PharmD
Cassie A. Barton, PharmD
Nathan Dominic Mah, PharmD
Carinda J. Feild, PharmD, FCCM
Bao Anh Tran
Keri J. Bicking, BCPS, PharmD, BCNSP
James C. McMillen, BCPS, PharmD
Eileen Shomo
Jeffrey P. Gonzales, BCPS, PharmD,
FCCM
David Nicolau, PharmD
Suprat Saely Wilson BCPS, PharmD
Volume 15 Issue 4
Abstract
Number
1206
1212
1217
1231
1241
1258
1260
1288
1293
1297
1313
December 2015
Title
Adjunctive Use of Ketamine during Extracorporeal
Membrane Oxygenation
Methemoglobinemia in acetaminophen overdose
and glucose-6-phosphate dehydrogenase deficiency
Extracorporeal Membrane Oxygenation for
Hemophagocytic Lymphohistiocytosis Secondary to
Ehrlichiosis
Lipid emulsion for inadvertent intrathecal
administration of local anesthetics in the ED
OTC sexual enhancement and poppers: a deadly
combination unknown to the public
Lipid rescue therapy and
hyperinsulinemia/euglycemia for atenolol and
zolpidem overdose
Neurosarcoidosis induced panhypopituitarism
Are children just little adults - the controversy of
pediatric ischemic stroke treatment
A System-wide Approach to Drug Price Inflation and
Therapeutic Alternatives
Cost Effectiveness of Intensive Care in the UK
Screening Weeks: A pilot trial management metric
CPP Authors
Tanna Hassig, BCPS
Joseph E. Mazur, PharmD, BCPS
Cara McDaniel, BCPS, PharmD
Pradip P. Kamat, MBA, MD
Ruchi Jain BCPS, PharmD
Scott W. Mueller, BCPS, PharmD
Melissa Heim, PharmD
Aanchal Kapoor, MD
Paras B. Khandhar, MD
Jennifer Anderson, ACNP
John Kinsella, MD
Jennifer Good, MD
Volume 15 Issue 4
December 2015
Miscellaneous Section
Technology Update
by Mona Patel, PharmD
The Society launched its first-ever Journal Club Twitter chat on October 29, 2015.
Christopher Seymour, MD, discussed his Critical Care Medicine article, “County-Level
Effects of Prehospital Regionalization of Critically Ill Patients: A Simulation Study.”
Anthony Gerlach, PharmD, who is also the Social Media Task Force Co-Chair,
moderated the session. The discussion generated 323 tweets and 472,644
impressions. The next Twitter chat will take place on December 15, 2015 at 2:00 p.m.
Central Time, when Azra Bihorac, MD, and Chuck Hobson, MD, will discuss their
Critical Care Medicine article, “Critical Care Delivery and ICU Structure: The Elephant
in the Room.” To participate, simply create an account or log in to Twitter and search
for #SCCMJC.
Frequently Asked Questions
by Justin Muir, PharmD
What electronic resources are available to optimize my experience at Congress?
 Download the SCCM Events app from the Google Play Store (Android) or
iTunes App Store (Apple) and take advantage of electronic schedules of
presentations, abstracts, and exhibits. Add events to your schedule to keep track
of all of the sessions and meetings you want to attend.
 Missed a session or poster? Log in to http://my.sccm.org and click on “My
Learning”. Use the links under the 45th Annual Congress heading for “Speaker
Presentations” and “Posters/Abstracts.” Electronic versions of posters, audio
recordings and slides from the individual presentations are available to those
who registered for Congress. On Demand resources will be posted shortly after
Congress has concluded.
Communications Committee members are charged with publishing the newsletter.
Thanks to the following members:
Simon Lam (chair)
Joanna Stollings (chair-elect)
Seth Bauer (member-at-large)
Katarzyna Adamczhk
Jerry Altshuler
Mahmoud Ammar
Abdalla Ammar
Scott Benken
Kim Berger
Prachi Bhatt
Aida ‘Rebecca’ Bickley
Jessica Crow
Deepali Dixit
Chris Droege
Diana Esaian
Stacey Folse
Marian Gaviola
Amanda Giancarelli
Gabrielle Gibson
Payal Gurnani
John Hammer
Drayton Hammond
Julie Kalabalik
Michael Kenes
Desiree Kosmisky
Jason Makii
Russell Mason
Thomas Moran
Justin Muir
Mona Patel
Natalie Prater
Kelli Rumbaugh
Abbi Smith
Volume 15 Issue 4
December 2015
Marilyn Bulloch
Tram Cat
Darlene Chaykosky
Tudy Hodgman
Lauren Igneri
Jessica Jones
Tom Smoot
Calvin Tucker
Sarah Welch
Patrick Welch
Featured CPP Resources
 Are you stuck on a research-related question?
Consider reaching out to the experts on the CPP
Research Committee by e-mailing
[email protected]
 Do you have a manuscript or grant that you would like
to be reviewed by a content expert? If so, consider emailing the Research Committee chair at
[email protected]
Upcoming SCCM Congress Meetings—Save the
Dates!
2016
2017
2018
February 20-24
January 21-25
February 24-28
Orlando, Florida
Honolulu, Hawaii
San Antonio, Texas